Docetaxel · Taxotere

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, HR+/HER2- Metastatic Breast Cancer, Metastatic Castration-Resistant Prostate Cancer, Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
EU
  • Breast cancer Taxotere in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with: operable node-positive breast cancer; operable node-negative breast cancer. For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer. Taxotere in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not...
Product first approved 1995EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (310)
Gastric Cancer
NCT01935778 · Asan Medical Center
2013-10-02 – 2028-06-30 · Gastric Cancer, Adjuvant Chemotherapy, XO
What this study did
NCT04447352 · Krankenhaus Nordwest
2020-12-17 – 2027-05-01 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT03961867 · Sixth Affiliated Hospital, Sun Yat-sen University
2020-09-15 – 2025-09 · Gastric Cancer
What this study did
NCT03221426 · Merck Sharp & Dohme LLC
2017-10-09 – 2025-04-23 · Gastric Cancer, Gastroesophageal Junction Cancer
What this study did
NCT04882241 · Merck Sharp & Dohme LLC
2020-07-29 – 2025-04-23 · Gastric Cancer, Gastroesophageal Junction Cancer
What this study did
NCT04351867 · LiNing
2020-09 – 2024-06 · Stomach Neoplasms
What this study did
NCT01515748 · Sanofi
2011-12-30 – 2021-12-13 · Gastric Cancer
What this study did
NCT02076594 · Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
2013-01 – 2018-12-31 · Locally Advanced Unresectable Gastric Cancer, Metastatic Gastric Cancer
What this study did
NCT03067792 · Yonsei University
2014-12 – 2016-10-17 · Inoperable Gastric Cancer
What this study did
NCT01283217 · Yonsei University
2010-03 – 2016-03 · Gastric Adenocarcinoma
What this study did
NCT00811447 · Sanofi
2008-11 – 2012-06 · Stomach Neoplasms
What this study did
NCT00287768 · Japan Clinical Cancer Research Organization
2006-03 – 2010-10 · Gastric Cancer
What this study did
NCT00978549 · Cambridge University Hospitals NHS Foundation Trust
2008-04 – 2010-10 · Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer, Nausea and Vomiting, Pain
What this study did
NCT00005060 · Swiss Cancer Institute
1999-11 – 2006-03 · Gastric Cancer
What this study did
Head and Neck Squamous Cell Carcinoma
NCT06102395 · Beijing Tongren Hospital
2023-05-01 – 2030-04-30 · Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab
What this study did
NCT00588770 · National Cancer Institute (NCI)
2008-08-08 – 2027-02-20 · Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Oral Cavity Verrucous Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Salivary Gland Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Major Salivary Gland Cancer AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Verrucous Carcinoma AJCC v7, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Major Salivary Gland Cancer AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Verrucous Carcinoma AJCC v7, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Major Salivary Gland Cancer AJCC v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Sinonasal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Verrucous Carcinoma AJCC v7, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVC Major Salivary Gland Cancer AJCC v7, Stage IVC Oral Cavity Cancer AJCC v6 and v7, Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Sinonasal Squamous Cell Carcinoma AJCC v7, Tongue Carcinoma
What this study did
NCT07371897 · Sun Yat-sen University
2026-06-30 – 2026-09-30 · Head and Neck Squamous Cell Carcinoma HNSCC
What this study did
NCT07435324 · R-Pharm
2024-08-08 – 2026-06-25 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT04780750 · Assiut University
2021-04-01 – 2022-09-01 · Squamous Cell Carcinoma of Head and Neck
What this study did
NCT00999700 · Gruppo Oncologico del Nord-Ovest
2009-09 – 2021-12 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT00995293 · Sanofi
2009-08-27 – 2018-01-26 · Head and Neck Neoplasms
What this study did
NCT00117572 · University of Chicago
2004-11 – 2016-12 · Cancer of the Pharynx, Cancer of the Larynx, Cancer of the Nasal Cavity, Paranasal Sinus Neoplasms, Cancer of the Oral Cavity
What this study did
NCT00041171 · Alliance for Clinical Trials in Oncology
— · Adult Solid Tumor, Breast Cancer, Head and Neck Cancer, Kidney and Urinary Cancer, Male Reproductive Cancer, Thorax and Respiratory Cancer
What this study did
NCT00003888 · European Organisation for Research and Treatment of Cancer - EORTC
1999-04 – 2015-03 · Head and Neck Cancer
What this study did
NCT00088907 · National Cancer Institute (NCI)
2004-08 – 2012-08 · Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
What this study did
NCT00095875 · Dana-Farber Cancer Institute
2004-08 – 2012-04 · Head and Neck Cancer
What this study did
NCT00113399 · Radiation Therapy Oncology Group
2005-04 – 2009-02 · Head and Neck Cancer
What this study did
NCT00268372 · SWOG Cancer Research Network
2005-12 – 2007-12 · Head and Neck Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05901428 · Fudan University
2023-06-01 – 2032-06 · Hormone Receptor Positive HER-2 Negative Breast Cancer
What this study did
NCT04540692 · Latin American Cooperative Oncology Group
2021-01-12 – 2030-10 · Breast Cancer
What this study did
NCT07805135 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2026-08-31 – 2029-06-01 · HER2-Negative Advanced Breast Cancer
What this study did
NCT04514419 · BioRay Pharmaceutical Co., Ltd.
2020-06-28 – 2025-12 · Breast Cancer
What this study did
NCT01547741 · NSABP Foundation Inc
2012-04 – 2025-10-17 · Breast Cancer
What this study did
NCT02003209 · National Cancer Institute (NCI)
2014-02-18 – 2025-06-30 · HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
What this study did
NCT02344472 · Prof. Wolfgang Janni
2015-09 – 2025-01-31 · Metastatic Breast Cancer
What this study did
NCT03863223 · Jiangsu HengRui Medicine Co., Ltd.
2019-04-22 – 2024-07-30 · Metastatic Breast Cancer
What this study did
NCT05985187 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2020-10-20 – 2023-12 · HER2-positive Breast Cancer
What this study did
NCT00667251 · Novartis Pharmaceuticals
2008-10-07 – 2022-07-27 · Breast Cancer
What this study did
NCT03084237 · Shanghai Henlius Biotech
2016-11 – 2021-09-28 · Breast Cancer
What this study did
NCT01917279 · Binghe Xu
2013-10 – 2021-07 · Breast Neoplasms, Neoplasms by Site, Neoplasm Metastasis, Breast Diseases, Skin Diseases
What this study did
NCT05301010 · Nanogen Pharmaceutical Biotechnology Joint Stock Company
2018-02-02 – 2021-02-19 · Breast Cancer Metastatic, Breast Cancer Recurrent, Breast Cancer Female
What this study did
NCT00703326 · Eli Lilly and Company
2008-08-06 – 2020-11-19 · Breast Cancer
What this study did
NCT00433589 · European Organisation for Research and Treatment of Cancer - EORTC
2007-02 – 2020-03 · Breast Cancer
What this study did
NCT02953340 · Spectrum Pharmaceuticals, Inc
2017-05-10 – 2019-05-06 · Neutropenia, Breast Cancer
What this study did
NCT02643420 · Spectrum Pharmaceuticals, Inc
2016-01-19 – 2018-10-31 · Neutropenia, Breast Cancer
What this study did
Phase 2/3 (50)
Gastric Cancer
NCT06028737 · Ukrainian Society of Clinical Oncology
2025-03-25 – 2032-12-31 · Gastric Cancer, Stomach Cancer, GastroEsophageal Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Advanced Gastric Adenocarcinoma, Gastric Neoplasm, Stomach Neoplasm, Gastrointestinal Cancer, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Gastric Carcinoma, Chemotherapy, Gastrectomy, Gastrectomy for Gastric Cancer, Gastric Resection, Gastric (Cardia, Body) Cancer
What this study did
NCT05427383 · Shanghai JMT-Bio Inc.
2022-04-07 – 2026-11 · Stomach Cancer
What this study did
NCT03607656 · Shanghai University of Traditional Chinese Medicine
2018-06-08 – 2023-11-30 · Gastric Cancer Stage IIIB, Gastric Cancer Stage IIIC
What this study did
Head and Neck Squamous Cell Carcinoma
NCT05063552 · National Cancer Institute (NCI)
2023-03-13 – 2027-12-15 · Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Lip and Oral Cavity Carcinoma, Metastatic Nasal Cavity Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Pharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Pharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
What this study did
NCT01810913 · National Cancer Institute (NCI)
2013-03-22 – 2027-01-01 · Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
What this study did
NCT00261703 · Sanofi
2002-12 – 2010-07 · Head and Neck Neoplasms
What this study did
NCT00401323 · Sanofi
1998-01 – 2003-06 · Head and Neck Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT03349177 · Zhiyong Yu
2017-11-27 – 2019-11-27 · Breast Cancer, Pathological Complete Response, Neoadjuvant Chemotherapy
What this study did
NCT00837265 · Teva Branded Pharmaceutical Products R&D, Inc.
2008-08-21 – 2009-06-26 · Chemotherapy-induced Neutropenia
What this study did
NCT00201435 · Norwegian Breast Cancer Group
2005-03 – 2008-05 · Breast Neoplasm
What this study did
Non-Small Cell Lung Cancer
NCT06616584 · SWOG Cancer Research Network
2025-05-22 – 2028-12-31 · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT06319313 · Shanghai JMT-Bio Inc.
2024-05-01 – 2027-12-01 · Squamous Cell Non-small Cell Lung Cancer
What this study did
NCT03178552 · Hoffmann-La Roche
2017-09-22 – 2027-06-30 · Non-Small Cell Lung Cancer
What this study did
NCT02326285 · AIO-Studien-gGmbH
2015-11 – 2018-01 · Non-squamous Non-small Cell Lung Cancer Stage II, Non-squamous Non-small Cell Lung Cancer Stage IIIA, Non-squamous Non-small Cell Lung Cancer Stage IIIB, Activating EGFR Mutation, NSCLC
What this study did
NCT02780778 · Tianjin Medical University Cancer Institute and Hospital
2016-05 – 2017-12 · Non-small Cell Lung Cancer
What this study did
NCT01774578 · NewLink Genetics Corporation
2013-02 – 2016-06-18 · Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent
What this study did
NCT01348126 · Synta Pharmaceuticals Corp.
2011-05 – 2015-10 · Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Metastatic
What this study did
NCT00030641 · Genta Incorporated
started 2001-10 · Lung Cancer
What this study did
Prostate Cancer
NCT06282588 · Cancer Research Antwerp
2023-12-13 – 2030-12-31 · Prostate Cancer
What this study did
NCT00268476 · Medical Research Council
2005-07-08 – 2030-12 · Prostate Cancer
What this study did
NCT03070886 · NRG Oncology
2017-04-05 – 2030-10-31 · Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
What this study did
NCT04787744 · VA Office of Research and Development
2021-07-01 – 2029-03-30 · Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
What this study did
NCT03258320 · Shanghai Jiao Tong University School of Medicine
2015-01 – 2027-12 · Prostate Cancer Patients
What this study did
NCT03879122 · Spanish Oncology Genito-Urinary Group
2019-02-11 – 2024-12-31 · Metastatic Hormone-sensitive Prostate Cancer
What this study did
NCT03295565 · The Netherlands Cancer Institute
2017-05-07 – 2022-03-02 · Prostate Cancer Metastatic, Metastasis
What this study did
NCT01603420 · Proton Collaborative Group
2012-07 – 2014-05 · Prostate Cancer
What this study did
NCT00043576 · Novacea
2002-08 – 2005-12 · Prostate Cancer
What this study did
Other / comorbidity
NCT06279130 · The Netherlands Cancer Institute
2024-01-29 – 2034-01-29 · Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors
What this study did
NCT06719479 · SUNHO(China)BioPharmaceutical CO., Ltd.
2025-01-01 – 2028-01-01 · NPC, HNSCC, Recurrence, Metastasis
What this study did
NCT02641847 · Fudan University
2016-01 – 2027-12 · Triple Negative Breast Cancer, Breast Cancer
What this study did
NCT03691454 · Peking University
2018-06-28 – 2027-06-30 · Gastric Adenocarcinoma
What this study did
NCT05189067 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2022-01-31 – 2025-06-30 · HER2-positive Breast Cancer, Adjuvant Therapy
What this study did
NCT03908372 · Chinese Academy of Medical Sciences
2019-06-15 – 2025-05 · Stage II, III, Nasopharyngeal Squamous Cell Carcinoma, Induction Chemotheray, Concurrent Chemoradiotherapy, Reduce Treatment Intensity
What this study did
NCT01779206 · Women's Cancer Study Group GmbH
2012-05 – 2025-01-15 · Breast Cancer
What this study did
NCT03600831 · Huai'an First People's Hospital
2018-08-20 – 2023-12-31 · Esophageal Squamous Cell Carcinoma
What this study did
NCT02923258 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
2018-04-21 – 2023-04-30 · Oral Cavity Squamous Cell Carcinoma
What this study did
NCT02661971 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2016-06 – 2022-06-20 · Stomach Cancer, Gastroesophageal Junction Cancer
What this study did
NCT04138992 · Air Force Military Medical University, China
2020-08-01 – 2022-05-31 · Disease Free Survival
What this study did
NCT01907529 · Hebei Medical University Fourth Hospital
2019-08 – 2021-12 · Stage III Breast Cancer
What this study did
NCT03373708 · Zhiyong Yu
2017-12-20 – 2019-12-20 · Breast Cancer, Chemotherapy, Endocrine Breast Diseases
What this study did
NCT02965378 · SWOG Cancer Research Network
2014-10 – 2019-10 · FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR2 Gene Amplification, FGFR2 Gene Mutation, FGFR3 Gene Amplification, FGFR3 Gene Mutation, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
What this study did
NCT02785939 · SWOG Cancer Research Network
2014-09 – 2019-06 · CCND1 Gene Amplification, CCND2 Gene Amplification, CCND3 Gene Amplification, CDK4 Gene Amplification, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
What this study did
NCT01999933 · Mei Shi
2013-11 – 2018-11 · Cervical Cancer, Toxicity Due to Radiotherapy
What this study did
NCT02099396 · China Association of Osteosarcoma Chemotherapy
2014-04 – 2016-06 · Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma
What this study did
NCT01150513 · Chinese Academy of Medical Sciences
2009-06 – 2016-04 · Breast Cancer
What this study did
NCT00525642 · Fudan University
2003-06 – 2015-06 · Breast Neoplasms, Adjuvant, Chemotherapy
What this study did
NCT01065870 · Columbia University
2009-12 – 2014-12 · Pancreatic Cancer Stage II, Pancreatic Cancer Stage III
What this study did
NCT00911352 · Princess Alexandra Hospital, Brisbane, Australia
2010-10 – 2012-12 · Effects of Chemotherapy
What this study did
Phase 2 (1048)
Gastric Cancer
NCT07257575 · Guangdong Provincial People's Hospital
2025-01-05 – 2031-06-30 · Gastric Cancer Stage III
What this study did
NCT07872722 · National Cancer Center, Japan
2026-08-13 – 2030-03-31 · CLDN18.2-Positive Gastric Cancer, CLDN18.2-Positive Gastroesophageal Junction Adenocarcinoma
What this study did
NCT02931890 · The Netherlands Cancer Institute
2017-12-21 – 2029-03 · Gastric Cancer
What this study did
NCT05715931 · Yu jiren
2023-05-30 – 2028-10-01 · Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, HER2-positive Gastric Cancer
What this study did
NCT04840264 · Sixth Affiliated Hospital, Sun Yat-sen University
2022-01-07 – 2028-06-30 · Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis
What this study did
NCT03505320 · Astellas Pharma Global Development, Inc.
2018-06-29 – 2028-05-31 · Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer, Pharmacokinetics of Oxaliplatin, Pharmacokinetics of Fluorouracil Bolus (5-FU)
What this study did
NCT03421288 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2018-09-14 – 2027-12-31 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06123338 · Memorial Sloan Kettering Cancer Center
2024-02-01 – 2027-11-30 · Esophageal Cancer, Gastric Adenocarcinoma, HER2 Gene Mutation
What this study did
NCT06947291 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2025-06-04 – 2027-10-30 · Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
What this study did
NCT05836584 · National Cancer Institute (NCI)
2023-12-06 – 2027-06-28 · Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT04354662 · Tianjin Medical University Cancer Institute and Hospital
2020-05-25 – 2026-07-06 · Gastric Cancer
What this study did
NCT04999332 · National Cheng-Kung University Hospital
2021-12-10 – 2025-12-31 · Gastric Cancer, Gastric Adenocarcinoma, Effects of Chemotherapy, Toxicity Due to Chemotherapy
What this study did
NCT04736485 · Centre Francois Baclesse
2021-06-28 – 2025-11-27 · Gastric Cancer by AJCC V8 Stage, Resectable Carcinoma
What this study did
NCT04781686 · Zhou Fuxiang
2021-05-14 – 2025-08 · Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
What this study did
NCT04062656 · University Hospital, Essen
2019-09-26 – 2025-06-01 · Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction
What this study did
NCT04547153 · Sixth Affiliated Hospital, Sun Yat-sen University
2021-01-15 – 2024-03-22 · Gastric Cancer, Bone Marrow Metastasis, Disseminated Intravascular Coagulation
What this study did
NCT04563975 · Tao Zhang
2020-07-02 – 2023-05-30 · Gastric Cancer Stage IV
What this study did
NCT04937738 · Ukrainian Society of Clinical Oncology
2021-07-21 – 2023-02-01 · Gastric Cancer
What this study did
NCT04770623 · Menoufia University
2021-03-05 – 2023-01-09 · Stomach Cancer, Gastric Cancer, Chemotherapy Effect
What this study did
NCT04152889 · RenJi Hospital
2020-04-14 – 2022-12 · Gastric Cancer Stage III
What this study did
NCT02555358 · Qun Zhao
2014-11 – 2022-06 · Gastric Cancer
What this study did
NCT02007148 · International Group of Endovascular Oncology
2013-11 – 2022-05 · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT03154983 · Zhou Fuxiang
2017-05-20 – 2021-12-31 · Metastatic Gastric Cancer
What this study did
NCT00952003 · Arbeitsgemeinschaft medikamentoese Tumortherapie
2009-07 – 2020-06 · Gastric Cancer, Unresectable
What this study did
NCT02623153 · Tianshu Liu
2016-01 – 2019-12 · Gastric Cancer
What this study did
NCT01498289 · SWOG Cancer Research Network
2012-02 – 2019-09-19 · Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
What this study did
NCT02725424 · Chinese Academy of Medical Sciences
2015-08 – 2019-06 · Gastric Cancer
What this study did
NCT00515411 · Memorial Sloan Kettering Cancer Center
2006-10-23 – 2018-10-26 · Gastroesophageal Junction Adenocarcinoma, Gastric Cancer
What this study did
NCT03137004 · Fujian Cancer Hospital
2017-06-01 – 2018-10-10 · Advanced Gastric Cancer
What this study did
NCT02485834 · Alliance for Clinical Trials in Oncology
2015-11-12 – 2018-08-01 · Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma, Gastric Cancer
What this study did
NCT01471470 · Asan Medical Center
2010-07 – 2018-07 · Advanced Gastric Cancer
What this study did
NCT00938470 · Alliance for Clinical Trials in Oncology
2010-01 – 2018-03 · Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
What this study did
NCT00674167 · National University Hospital, Singapore
2007-05 – 2017-12 · Gastric Cancer
What this study did
NCT02289378 · Sixth Affiliated Hospital, Sun Yat-sen University
2014-11 – 2017-10 · Docetaxel, Oxaliplatin and Fluorouracil
What this study did
NCT01836120 · Hebei Tumor Hospital
2013-04 – 2017-06 · Gastric Cancer
What this study did
NCT01715233 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2012-12 – 2017-04 · Metastatic Esophageal Cancer, Gastroesophageal Cancer, Gastric Cancer
What this study did
NCT00394433 · Dana-Farber Cancer Institute
2006-09 – 2016-10 · Esophageal Cancer, Stomach Cancer
What this study did
NCT02004769 · Sun Yat-sen University
2013-11 – 2016-06 · Stomach Neoplasms, Neoplasms Metastasis, ERBB2 Gene Amplification
What this study did
NCT01967875 · China Medical University, China
2013-07 – 2016-05 · Stomach Neoplasms
What this study did
NCT01624025 · Yonsei University
2012-06 – 2016-02 · Metastatic Advanced Gastric Cancer
What this study did
NCT00849615 · Krankenhaus Nordwest
2009-02 – 2016-01 · Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction
What this study did
NCT00183872 · University of Southern California
2005-04-14 – 2015-10-20 · Gastric Cancer, Esophageal Neoplasms
What this study did
NCT00414271 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2006-01 – 2015-10 · Stage T3-4NxM0 Gastric Cancer
What this study did
NCT00865982 · Charite University, Berlin, Germany
2008-09 – 2015-09 · Gastric Cancer, Esophageal Cancer
What this study did
NCT01359397 · The Netherlands Cancer Institute
2011-03 – 2015-05 · Metastatic Gastric Cancer, Adenocarcinoma of the Gastro-oesophageal Junction
What this study did
NCT01718626 · Hebei Tumor Hospital
2012-10 – 2014-12 · Gastric Cancer
What this study did
NCT01963702 · Fudan University
2012-08 – 2014-12 · Gastric Cancer
What this study did
NCT01160419 · Ludwig-Maximilians - University of Munich
2009-12 – 2014-05 · Gastric Cancer
What this study did
Phase 1/2 (177)
Gastric Cancer
NCT06732856 · Asan Medical Center
2025-04-04 – 2027-12-31 · Stomach Neoplasm, Gastric (Stomach) Cancer
What this study did
NCT03606928 · Ruijin Hospital
2018-07-01 – 2020-01-01 · Gastric Cancer
What this study did
NCT01921673 · Asan Medical Center
2013-08 – 2016-10 · Gastric Cancer
What this study did
NCT01525771 · Asan Medical Center
2011-02 – 2014-12 · Stage IV Gastric Cancer With Metastasis
What this study did
NCT00845884 · Rabin Medical Center
2009-02 – 2012-12 · Advanced Gastric Cancer
What this study did
NCT00711243 · Northwestern University
2005-04-20 – 2011-02-25 · Gastric Cancer, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00209729 · Hokkaido Gastrointestinal Cancer Study Group
2005-04 – 2010-03 · Gastric Cancer
What this study did
NCT00533533 · Samsung Medical Center
2006-01 – 2008-06 · Gastric Cancer
What this study did
Head and Neck Squamous Cell Carcinoma
NCT04895709 · Bristol-Myers Squibb
2021-05-27 – 2031-08-31 · Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms
What this study did
NCT06943820 · Akeso
2025-05-21 – 2028-05 · Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma, Advanced Solid Tumors
What this study did
NCT05910827 · Hummingbird Bioscience
2024-02-05 – 2027-12 · Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Nasopharyngeal Cancinoma (NPC), Squamous Cell Carcinoma
What this study did
NCT05714553 · NuCana plc
2023-03-08 – 2025-05-30 · Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant, Metastatic Cancer, Melanoma, Classical Hodgkin Lymphoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Subungual Squamous Cell Carcinoma, Oesophageal Carcinoma, MSI-H Colorectal Cancer, Gastric Cancer, Triple Negative Breast Cancer, Endometrial Carcinoma, Pleural Mesothelioma
What this study did
NCT05094804 · OncoResponse, Inc.
2021-09-09 – 2024-08-15 · Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Leiomyosarcoma, Liposarcoma
What this study did
NCT05027204 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2022-03-04 – 2023-12-31 · Squamous Cell Carcinoma of Head and Neck
What this study did
NCT02718820 · Medical University of Vienna
2016-03 – 2021-12 · Head and Neck Carcinoma
What this study did
NCT00982436 · University of Vermont
2009-09 – 2012-12 · Head and Neck Neoplasms
What this study did
NCT01313390 · University College, London
2009-06 – 2011-04 · Head and Neck Cancer
What this study did
NCT00498953 · European Organisation for Research and Treatment of Cancer - EORTC
2007-05 – 2009-03 · Head and Neck Cancer
What this study did
NCT00318890 · University of Alabama at Birmingham
2002-10 – 2007-12 · Cancer of Head and Neck, Head Cancer, Head and Neck Cancer, Neck Cancer, Neck Neoplasms
What this study did
NCT00055770 · National Cancer Institute (NCI)
2002-10 – 2006-12 · Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Salivary Gland Squamous Cell Carcinoma, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
What this study did
NCT00139269 · Dana-Farber Cancer Institute
1998-02 – 2006-12 · Advanced Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, SSCHN
What this study did
NCT00268671 · Sanofi
2003-08 – 2006-04 · Head and Neck Neoplasms
What this study did
NCT00139243 · Dana-Farber Cancer Institute
1997-10 – 2006-01 · Squamous Cell Carcinoma, Carcinoma of Head and/or Neck
What this study did
NCT00003103 · Memorial Sloan Kettering Cancer Center
1997-08 – 2002-08 · Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT04140526 · OncoC4, Inc.
2020-09-16 – 2027-12-31 · Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
What this study did
NCT05381038 · National University Hospital, Singapore
2023-02-13 – 2027-04-04 · Solid Tumor, Gastrointestinal Cancer, Breast Cancer
What this study did
NCT04276493 · BeiGene
2020-03-23 – 2024-10-31 · Breast Cancer, Gastric Cancer, Gastroesophageal Junction Cancer
What this study did
NCT02229084 · University of Arkansas
2015-01-14 – 2023-01-03 · Breast Cancer, Breast Neoplasms
What this study did
NCT02393248 · Incyte Corporation
2015-02-27 – 2021-12-17 · Lung Cancer, Solid Tumor, Gastric Cancer, Urothelial Cancer, Endometrial Cancer, Multiple Myeloma, Myeloproliferative Neoplasms, Breast Cancer, Cholangiocarcinoma, UC, MPN
What this study did
NCT02331251 · Western Regional Medical Center
2014-12 – 2018-01 · Advanced Cancer, Breast Cancer, Sarcoma, Pancreatic Cancer, Small Cell Lung Cancer, Ovarian
What this study did
NCT00086957 · City of Hope Medical Center
2004-01 – 2015-08 · Breast Cancer
What this study did
NCT02379585 · Western Regional Medical Center
2013-01 – 2015-08 · HER2-positive Breast Cancer
What this study did
NCT00066443 · NCIC Clinical Trials Group
2003-11-03 – 2014-01-16 · Breast Cancer
What this study did
NCT00934856 · Hoffmann-La Roche
2009-07 – 2013-10 · Breast Cancer
What this study did
NCT00645333 · University of Michigan Rogel Cancer Center
2008-03 – 2012-10 · Metastatic Breast Cancer
What this study did
NCT01044485 · Centre Georges Francois Leclerc
2008-11 – 2011-11 · Metastatic Breast Cancer
What this study did
NCT00070252 · National Cancer Institute (NCI)
2003-09 – 2010-06 · Adult Solid Neoplasm, Inflammatory Breast Carcinoma, Male Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
What this study did
NCT00705315 · Hellenic Oncology Research Group
2008-05 – 2010-06 · Breast Cancer
What this study did
NCT00539968 · Merck Sharp & Dohme LLC
2007-06 – 2009-12 · Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Gastric Cancer
What this study did
NCT00076024 · Pfizer
2004-02 – 2008-11 · Breast Neoplasms
What this study did
NCT00063934 · National Cancer Institute (NCI)
2003-05 – 2008-02 · Male Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
What this study did
NCT00217815 · NeuTec Pharma
2005-09 – 2006-10 · Cancer of the Breast
What this study did
NCT00020332 · National Cancer Institute (NCI)
2000-10 – 2003-03 · Breast Cancer
What this study did
Metastatic Castration-Resistant Prostate Cancer
NCT07667400 · National Cancer Institute (NCI)
2026-11-24 – 2037-10-01 · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Paranasal Sinus Neoplasms, Nasopharyngeal Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Hypopharyngeal Cancer, Carcinoma of Larynx, Oral Squamous Cell Carcinoma, Salivary Gland Cancer, Adenoid Cystic Carcinoma, Prostate Cancer, Metastatic Castration Resistant Prostate Cancer
What this study did
NCT06353386 · Merck Sharp & Dohme LLC
2024-05-20 – 2029-01-15 · Prostatic Neoplasms, Castration-Resistant
What this study did
NCT02861573 · Merck Sharp & Dohme LLC
2016-11-17 – 2028-07-24 · Metastatic Castration-Resistant Prostate Cancer
What this study did
NCT06480110 · Copenhagen University Hospital, Rigshospitalet
2024-06-20 – 2027-12-01 · Metastatic Castration-resistant Prostate Cancer
What this study did
NCT02565901 · University of Washington
2016-02-29 – 2020-06-16 · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7, Metastatic Malignant Neoplasm in the Bone
What this study did
NCT01084655 · Millennium Pharmaceuticals, Inc.
2010-07 – 2016-03 · Prostate Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07472647 · Shanghai JMT-Bio Inc.
2026-02-28 – 2030-02-28 · Non-Small Cell Lung Cancer, Small Cell Lung Cancer
What this study did
Phase 1 (315)
Gastric Cancer
NCT05296005 · Ohio State University Comprehensive Cancer Center
2025-12-31 – 2025-12-31 · Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8, Clinical Stage IIB Gastric Cancer AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Gastric Adenocarcinoma, Pathologic Stage IB Gastric Cancer AJCC v8, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Gastric Cancer AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastric Cancer AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastric Cancer AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
What this study did
NCT04583488 · Johns Hopkins University
2020-11-01 – 2024-08-06 · Peritoneal Carcinomatosis
What this study did
NCT05327231 · InxMed (Shanghai) Co., Ltd.
2020-07-09 – 2022-03-31 · Gastric Cancer
What this study did
NCT02024841 · The University of Hong Kong
2013-12 – 2018-03 · Gastric Cancer, Peritoneal Carcinomatosis
What this study did
NCT02378389 · Jiangsu HengRui Medicine Co., Ltd.
2014-09 – 2017-08 · HER2 Positive Gastric Cancer
What this study did
NCT02252913 · Hutchison Medipharma Limited
2014-09 – 2015-12 · Gastric Cancer
What this study did
Head and Neck Squamous Cell Carcinoma
NCT05076760 · Memgen, Inc.
2022-04-21 – 2031-12 · Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer
What this study did
NCT07358806 · Oscotec Inc.
2025-12-18 – 2027-12 · Solid Tumor, Breast Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Gastric/Gastroesophageal Junction Cancer
What this study did
NCT04722523 · Memorial Sloan Kettering Cancer Center
2021-01-20 – 2027-06-20 · Head and Neck Cancer, Head Cancer, Head Cancer Neck, Neck Cancer, Head and Neck Squamous Cell Carcinoma, HNSCC
What this study did
NCT02495896 · University of Southern California
2015-09-03 – 2026-12-31 · Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage III Pancreatic Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Gallbladder Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Pancreatic Cancer, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Cancer
What this study did
NCT05376553 · Krzysztof Misiukiewicz
2022-07-20 – 2025-10 · Locally Advanced Head and Neck Squamous Cell Carcinoma
What this study did
NCT07435311 · R-Pharm
2020-06-15 – 2024-07-17 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT05552807 · Sinocelltech Ltd.
2022-06-15 – 2023-09 · Head and Neck Squamous Carcinoma
What this study did
NCT02997332 · Gustave Roussy, Cancer Campus, Grand Paris
2017-03-30 – 2022-12-01 · Head and Neck Cancers
What this study did
NCT01783587 · Dana-Farber Cancer Institute
2013-02 – 2018-06-01 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT02508246 · University of Washington
2015-07-22 – 2018-04-26 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT02921984 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
2013-09 – 2017-08 · Salivary Gland Tumors, Head and Neck Cancer
What this study did
NCT02035527 · Ohio State University Comprehensive Cancer Center
2014-04-14 – 2017-04-20 · Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Oral Cavity Squamous Cell Carcinoma, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
What this study did
NCT02110992 · University of Cincinnati
2014-04 – 2017-03-29 · Head and Neck Cancer
What this study did
NCT01172028 · University of Arizona
2005-09 – 2014-07 · Breast Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
What this study did
NCT00935961 · Memorial Sloan Kettering Cancer Center
2009-07 – 2013-08 · HEAD & NECK Cancer
What this study did
NCT00513383 · Massachusetts General Hospital
2006-04 – 2012-10 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT01149902 · University of Yamanashi
2010-07 – 2012-03 · Head and Neck Cancer
What this study did
NCT00113347 · M.D. Anderson Cancer Center
2005-04 – 2011-04 · Head and Neck Cancer
What this study did
NCT00405405 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2006-12 – 2010-06 · Head and Neck Cancer, Parotid Gland Cancer, Thyroid Gland Cancer, Melanoma, Stage IV Head and Neck Cancer
What this study did
NCT00002901 · City of Hope Medical Center
started 1996-12 · Breast Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00937417 · SWOG Cancer Research Network
2008-09 – 2009-09 · Breast Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00402545 · Dana-Farber Cancer Institute
2007-01 – 2009-07 · Head and Neck Neoplasms
What this study did
NCT00003200 · Dana-Farber Cancer Institute
1995-10 – 2008-06 · Head and Neck Cancer
What this study did
NCT00049283 · National Cancer Institute (NCI)
2002-09 – 2008-02 · Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
What this study did
NCT00014456 · Dartmouth-Hitchcock Medical Center
2000-03 – 2005-10 · Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
What this study did
NCT00006107 · Dana-Farber Cancer Institute
2000-07-14 – 2004-07-03 · Head and Neck Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT00600496 · AstraZeneca
2007-12-14 – 2025-12-18 · Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer, Colon Neoplasms, Lung Cancer, Melanoma, Kidney Cancer
What this study did
NCT04187898 · Spectrum Pharmaceuticals, Inc
2020-03-11 – 2024-08-16 · Neutropenia, Breast Cancer
What this study did
NCT02009449 · Eli Lilly and Company
2013-11-15 – 2023-07-22 · Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer
What this study did
NCT04367090 · Jiangsu HengRui Medicine Co., Ltd.
2020-05-28 – 2023-05-24 · Metastatic Breast Cancer
What this study did
NCT05622058 · Aileron Therapeutics, Inc.
2023-01-09 – 2023-02-22 · Prevention of Chemotherapy-induced Myelosuppression
What this study did
NCT00251433 · Novartis Pharmaceuticals
2005-09-26 – 2022-06-22 · Neoplasms, Breast
What this study did
NCT05301530 · Nanogen Pharmaceutical Biotechnology Joint Stock Company
2019-05-27 – 2021-02-19 · Breast Cancer Metastatic, Breast Cancer Female, Breast Cancer Recurrent
What this study did
NCT03135951 · Spectrum Pharmaceuticals, Inc
2017-05-11 – 2018-05-18 · Breast Cancer, Pharmacokinetics
What this study did
NCT01880385 · Association Tunisienne de lutte Contre le Cancer
2011-03 – 2017-04 · Inflammatory Breast Cancer
What this study did
NCT01876251 · Pfizer
2013-11-04 – 2015-12-24 · Breast Cancer Metastatic
What this study did
NCT01539876 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
— · Breast Cancer
What this study did
NCT00637897 · Wake Forest University Health Sciences
2008-03 – 2013-03 · Breast Cancer
What this study did
NCT01256567 · Eli Lilly and Company
2010-12 – 2013-02 · Breast Cancer, Metastatic Breast Cancer
What this study did
NCT00949247 · Case Comprehensive Cancer Center
2009-12 – 2013-01 · Breast Cancer
What this study did
NCT00253318 · M.D. Anderson Cancer Center
2005-11-01 – 2012-04 · Breast Cancer
What this study did
NCT00322400 · Amgen
2006-03 – 2012-01 · Locally Recurrent and Metastatic Breast Cancer
What this study did
NCT01041235 · Azaya Therapeutics, Inc.
2009-12 – 2011-12 · Solid Tumor, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung
What this study did
Phase 4 (30)
Head and Neck Squamous Cell Carcinoma
NCT02484677 · Assistance Publique Hopitaux De Marseille
2015-07-15 – 2023-05-25 · Patients With Head and Neck Cancer (ORL)
What this study did
NCT04766827 · Tianjin Medical University Cancer Institute and Hospital
2020-12-12 – 2021-12 · Squamous Cell Carcinoma of Head and Neck
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT02627248 · Shandong University
2015-10 – 2025-10 · Breast Cancer
What this study did
NCT02419742 · Hoffmann-La Roche
2015-08-18 – 2021-06-24 · Breast Cancer
What this study did
NCT02502864 · H. Lee Moffitt Cancer Center and Research Institute
2016-02-09 – 2019-01-31 · Breast Cancer, Breast Cancer Female
What this study did
NCT02445586 · Hoffmann-La Roche
2015-08-17 – 2018-09-26 · Breast Cancer
What this study did
NCT00774241 · Hoffmann-La Roche
2010-01 – 2013-11 · Breast Cancer
What this study did
NCT00127933 · Hoffmann-La Roche
2005-08 – 2009-07 · Breast Cancer
What this study did
Metastatic Castration-Resistant Prostate Cancer
NCT03641560 · Astellas Pharma Inc
2018-09-19 – 2024-02-20 · Metastatic Castration Resistant Prostate Cancer
What this study did
NCT02441517 · Astellas Pharma Global Development, Inc.
2015-10-28 – 2017-03-15 · Metastatic Castration Resistant Prostate Cancer
What this study did
Non-Small Cell Lung Cancer
NCT03799601 · Tongji Hospital
2019-03-01 – 2020-12-01 · NSCLC
What this study did
NCT02031601 · Qilu Hospital of Shandong University
2014-01 – 2017-12 · Non-Small-Cell Lung Cancer
What this study did
NCT02283424 · Chinese PLA General Hospital
2014-10 – 2017-12 · Neoplasms, Therapy-Associated
What this study did
NCT00883675 · Michael Mann
2009-05 – 2012-12 · Non-small Cell Lung Cancer
What this study did
NCT01442909 · Taipei Veterans General Hospital, Taiwan
2008-03 – 2009-09 · Non-small-cell Lung Cancer
What this study did
Prostate Cancer
NCT00280098 · Sanofi
2006-01 – 2007-10 · Prostatic Neoplasms
What this study did
Other / comorbidity
NCT07093931 · Shandong Cancer Hospital and Institute
2025-08-01 – 2030-08-01 · Breast Cancer
What this study did
NCT04137640 · Shengjing Hospital
2021-07-19 – 2026-05-31 · Breast Cancer
What this study did
NCT05302336 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2022-05-01 – 2024-12-30 · Breast Cancer, Chemotherapeutic Toxicity
What this study did
NCT03123770 · Zhejiang University
2016-12 – 2021-12 · Breast Cancer
What this study did
NCT02513342 · Nanjing NingQi Medicine Science and Technology Co., Ltd.
2015-03 – 2018-04 · Advanced Lung Squamous Carcinoma
What this study did
NCT03069820 · Second Affiliated Hospital of Nanchang University
2017-02-10 – 2018-01-01 · Liver Injury, Drug-Induced
What this study did
NCT01501487 · Agendia
2011-10 – 2017-06 · Breast Cancer
What this study did
NCT02088515 · Jiangsu Simcere Pharmaceutical Co., Ltd.
2013-12 – 2017-02 · Squamous Cell Carcinoma
What this study did
NCT01094184 · Hoffmann-La Roche
2010-03 – 2015-12 · Breast Cancer
What this study did
NCT01298193 · Spanish Breast Cancer Research Group
2011-05 – 2014-04 · Breast Cancer
What this study did
NCT00772681 · Sanofi
2004-10 – 2008-03 · Head and Neck Neoplasms
What this study did
Early phase / not applicable (45)
Gastric Cancer
NCT02640898 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2015-12 – 2022-12 · Gastric Cancer
What this study did
NCT02358863 · Georgetown University
2015-02 – 2016-11 · Esophageal Cancer, Gastric Cancer
What this study did
Head and Neck Squamous Cell Carcinoma
NCT00502463 · Austrian South Oncology Group
2007-10-03 – 2014-01-19 · Head and Neck Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT04324346 · Swedish Red Cross University College
2016-04-01 – 2021-02-01 · Catheter Related Complications
What this study did
NCT02283983 · Centre Hospitalier Departemental Vendee
2014-12 – 2020-06-25 · Breast Neoplasms
What this study did
NCT01891123 · Sun Yat-sen University
2013-06 – 2016-12 · Non-small Cell Lung Cancer, Breast Cancer, Nasal Cancer
What this study did
NCT03017404 · Hebei Medical University Fourth Hospital
2015-05 – 2016-07 · Breast Cancer
What this study did
NCT02870699 · Institut de Cancérologie de Lorraine
2011-10 – 2016-06 · Breast Carcinoma
What this study did
NCT00681993 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2008-04 – 2016-03-04 · Breast Cancer
What this study did
NCT00911716 · Cancer Trials Ireland
2008-10 – 2015-09 · Breast Cancer
What this study did
NCT00535509 · King Faisal Specialist Hospital & Research Center
2007-06 – 2013-06 · Breast Cancer
What this study did
NCT00309920 · Heinrich-Heine University, Duesseldorf
started 2004-01 · Breast Cancer
What this study did
NCT00538525 · King Faisal Specialist Hospital & Research Center
2007-09 – 2008-04 · Breast Cancer
What this study did
NCT00079170 · National Cancer Institute (NCI)
2004-01 – 2007-10 · Breast Cancer
What this study did
NCT00310089 · National Cancer Institute (NCI)
2006-01 – 2007-07 · Breast Cancer
What this study did
NCT00156312 · University of Michigan Rogel Cancer Center
2003-07 – 2007-02 · Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT06576635 · University of Illinois at Chicago
2024-12-16 – 2026-09 · NSCLC
What this study did
NCT03566576 · Fujian Cancer Hospital
2018-07-01 – 2018-10-01 · Non-squamous Non-small Cell Lung Cancer
What this study did
NCT02145078 · Barbara Ann Karmanos Cancer Institute
2014-06 – 2017-03-07 · Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
What this study did
NCT01209520 · University of Miami
2009-07 – 2013-12 · Lung Cancer, Non Small Cell Lung Carcinoma, Hypermethylation
What this study did
NCT00675597 · Memorial Sloan Kettering Cancer Center
2008-05 – 2012-02 · Lung Cancer
What this study did
NCT00883480 · Spanish Lung Cancer Group
2005-06 – 2008-11 · Non-small Cell Lung Cancer
What this study did
NCT01004601 · Chang Gung Memorial Hospital
2005-03 – 2008-10 · Non Small Cell Lung Cancer
What this study did
Prostate Cancer
NCT07172685 · Qilu Hospital of Shandong University
2025-07-30 – 2027-06-30 · Prostate Cancer
What this study did
NCT01040624 · University of Florida
2009-12 – 2022-04-11 · Prostate Cancer
What this study did
NCT02208583 · Tianjin Medical University Cancer Institute and Hospital
2014-06 – 2016-12 · Hormone Refractory Prostate Cancer
What this study did
NCT01530295 · Hanjong Ahn
2008-07 – 2012-07 · Prostate Cancer
What this study did
NCT00870714 · Kansas City Veteran Affairs Medical Center
2004-09 – 2010-09 · Prostate Cancer
What this study did
Other / comorbidity
NCT05800054 · The First Affiliated Hospital with Nanjing Medical University
2021-01-01 – 2027-12-31 · Esophageal Neoplasms, Adverse Drug Event
What this study did
NCT05494190 · Eye & ENT Hospital of Fudan University
2022-11-01 – 2027-11 · Hypopharyngeal Carcinoma
What this study did
NCT05914753 · Zhejiang Provincial People's Hospital
2023-07-01 – 2025-06-01 · Breast Cancer, Chemotherapy Effect
What this study did
NCT05671900 · Clinical Hospital Centre Zagreb
2020-04-01 – 2024-12 · Non-muscle-invasive Bladder Cancer
What this study did
NCT01503905 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2011-12 – 2021-12 · Breast Cancer Nos Premenopausal
What this study did
NCT03847818 · Shandong University
2019-03-01 – 2021-02-28 · HER2-positive Breast Cancer
What this study did
NCT03177174 · Luo yanrong
2017-06-12 – 2020-02-01 · Drug-Related Side Effects and Adverse Reactions
What this study did
NCT01295086 · Odense University Hospital
2011-03 – 2018-01 · Adenocarcinoma
What this study did
NCT03221881 · Hebei Medical University Fourth Hospital
2015-01 – 2017-06 · Breast Cancer
What this study did
NCT01958580 · Albert Einstein College of Medicine
2013-09-17 – 2017-02-24 · Stage IA Uterine Sarcoma, Stage IB Uterine Sarcoma, Stage IC Uterine Sarcoma, Stage IIA Uterine Sarcoma, Stage IIB Uterine Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Corpus Leiomyosarcoma
What this study did
NCT01448759 · Institut Curie
2011-10 – 2012-02 · Tumors
What this study did
NCT00614835 · Memorial Sloan Kettering Cancer Center
2001-08 – 2012-01 · Uterine Leiomyosarcoma, Uterine Cancer
What this study did
NCT01008774 · Sanofi
2009-07 – 2011-10 · Neoplasms, Alopecia
What this study did
NCT00159471 · University of Southern California
2005-02 – 2006-07 · Pancreatic Cancer
What this study did
Used as active comparator (297)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (163)
Gastric Cancer
NCT07366528 · Ruijin Hospital
2025-12-15 – 2030-10-31 · Gastric Cancer (GC), Adjuvant Chemotherapy, Stage 3 Cancer, Docetaxel, Oxaliplatin
What this study did
NCT07518147 · Biokin (Shanghai) Biopharmaceutical Co., Ltd.
2026-05-15 – 2029-12 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06123494 · Jiangsu HengRui Medicine Co., Ltd.
2024-01-09 – 2027-06-30 · HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06296706 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2024-02-27 – 2027-06-01 · Gastric Cancer
What this study did
NCT06346392 · AstraZeneca
2024-03-04 – 2026-10-14 · Gastric Cancer, Gastroesophageal Junction Cancer
What this study did
Head and Neck Squamous Cell Carcinoma
NCT03340896 · Groupe Oncologie Radiotherapie Tete et Cou
2015-06-25 – 2028-11 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT06699212 · Rakuten Medical, Inc.
2024-12-24 – 2028-09 · Recurrent Head and Neck Squamous Cell Carcinoma
What this study did
NCT02252042 · Merck Sharp & Dohme LLC
2014-11-17 – 2022-08-15 · Head and Neck Squamous Cell Cancer
What this study did
NCT02105636 · Bristol-Myers Squibb
2014-05-29 – 2021-09-10 · Squamous Cell Carcinoma of the Head and Neck
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07432178 · Fudan University
2026-04-03 – 2034-03-31 · Breast Cancer
What this study did
NCT06079983 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd
2023-12-01 – 2029-03-01 · Breast Cancer
What this study did
NCT04400695 · RemeGen Co., Ltd.
2020-09-29 – 2027-12-31 · Breast Cancer
What this study did
NCT05430399 · Sun Yat-sen University
2022-06-21 – 2027-06-01 · Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer
What this study did
NCT01646034 · The Netherlands Cancer Institute
2014-09 – 2026-10 · Breast Cancer
What this study did
NCT03264547 · Japan Breast Cancer Research Group
2017-08-28 – 2024-12-31 · Breast Cancer
What this study did
NCT00630032 · UNICANCER
2007-09 – 2020-09-03 · Breast Cancer
What this study did
NCT00393939 · Pfizer
2007-02 – 2011-07 · Breast Neoplasms
What this study did
Metastatic Castration-Resistant Prostate Cancer
NCT07213674 · Amgen
2025-11-28 – 2032-08-30 · Metastatic Castration-resistant Prostate Cancer
What this study did
NCT07365995 · BioNTech SE
2026-04-22 – 2031-02 · Metastatic Castration-resistant Prostate Cancer
What this study did
NCT07723248 · ORIC Pharmaceuticals
2026-08-03 – 2030-09 · Metastatic Castration Resistant Prostate Cancer
What this study did
NCT06764485 · Celgene
2025-03-13 – 2029-01-19 · Metastatic Castration-resistant Prostate Cancer
What this study did
NCT02975934 · pharmaand GmbH
2017-06-13 – 2024-08-08 · Metastatic Castration Resistant Prostate Cancer
What this study did
NCT01308567 · Sanofi
2011-05-05 – 2018-05 · Prostate Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07144280 · Pfizer
2025-09-29 – 2032-03-10 · Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
What this study did
NCT07660094 · Candel Therapeutics, Inc.
2026-06-15 – 2031-10-22 · Non-squamous, Non-Small Cell Lung Cancer
What this study did
NCT07442565 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-03-10 – 2031-05-30 · Non-Small Cell Lung Cancer
What this study did
NCT07668752 · Genfleet Therapeutics (Shanghai) Inc.
2026-07-27 – 2031-04-30 · KRAS G12D Mutation, NSCLC (Non-small Cell Lung Cancer)
What this study did
NCT06881784 · Revolution Medicines, Inc.
2025-05-06 – 2030-12-01 · NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT07566052 · Astellas Pharma Global Development, Inc.
2026-08-19 – 2030-06-30 · Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT06074588 · Merck Sharp & Dohme LLC
2023-11-12 – 2030-03-11 · Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT07242274 · Jemincare
2025-12-31 – 2029-12-30 · NSCLC (Non-small Cell Lung Cancer)
What this study did
NCT07524257 · ImmunityBio, Inc.
2026-05-29 – 2029-12-30 · NSCLC (Advanced Non-small Cell Lung Cancer), Metastatic NSCLC
What this study did
NCT07831863 · Mabwell (Shanghai) Bioscience Co., Ltd.
2026-10 – 2029-12 · Lung Squamous Cell Carcinoma
What this study did
NCT07291037 · AstraZeneca
2025-10-31 – 2029-01-29 · Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT05378763 · Spectrum Pharmaceuticals, Inc
2022-05-12 – 2028-12-25 · NSCLC
What this study did
NCT06472245 · OSE Immunotherapeutics
2024-12-03 – 2028-12-15 · Patients With Non-Small Cell Lung Cancer
What this study did
NCT06635824 · Genmab
2024-11-25 – 2028-09-30 · PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
What this study did
NCT05671510 · OncoC4, Inc.
2023-06-28 – 2028-08-31 · Non Small Cell Lung Cancer
What this study did
NCT07416994 · MediLink Therapeutics (Suzhou) Co., Ltd.
2026-03-18 – 2028-08-31 · Non-Small Cell Lung Cancer
What this study did
NCT06908993 · Intergroupe Francophone de Cancerologie Thoracique
2025-12-09 – 2028-07-15 · Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation
What this study did
NCT06012435 · Seagen, a wholly owned subsidiary of Pfizer
2024-02-21 – 2028-05-17 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT05450692 · AstraZeneca
2022-09-15 – 2027-12-31 · Advanced or Metastatic Non-Small Cell Lung Cancer
What this study did
NCT06908304 · Maia Biotechnology
2025-12-08 – 2027-12-31 · Carcinoma, Non-Small -Cell Lung
What this study did
NCT06300177 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2024-03-28 – 2027-12 · Non Small Cell Lung Cancer
What this study did
NCT04656652 · Daiichi Sankyo
2020-12-21 – 2027-02-15 · Non-small Cell Lung Cancer
What this study did
Phase 2/3 (20)
Gastric Cancer
NCT02409199 · Shanghai Zhongshan Hospital
2015-06 – 2017-03 · Gastric Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT07459751 · Shanghai Henlius Biotech
2026-05-27 – 2030-01-15 · Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
What this study did
NCT05096663 · SWOG Cancer Research Network
2022-03-15 – 2027-12-01 · Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT05001724 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd
2021-10-28 – 2023-04-07 · Advanced Non-small Cell Lung Cancer
What this study did
NCT03288870 · Biocad
2017-09-19 – 2021-08-10 · Non Small Cell Lung Cancer Stage IIIB, Non-Small Cell Carcinoma of Lung, TNM Stage 4
What this study did
NCT01905657 · Merck Sharp & Dohme LLC
2013-08-09 – 2020-09-30 · Non Small Cell Lung Cancer (NSCLC)
What this study did
NCT02959749 · Qingdao Central Hospital
2015-08 – 2017-12-31 · Progression Free Survival
What this study did
Prostate Cancer
NCT07852195 · ECOG-ACRIN Cancer Research Group
2027-01-06 – 2030-03-31 · Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
What this study did
Other / comorbidity
NCT02568839 · Thomas Hatschek
2014-11 – 2029-02 · Early-Stage Breast Carcinoma, HER-2 Positive Breast Cancer
What this study did
NCT06891833 · Sichuan Baili Pharmaceutical Co., Ltd.
2025-06-05 – 2028-12 · HER2-positive Breast Cancer
What this study did
NCT04576143 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2020-09-20 – 2027-09-20 · HER2-negative Breast Cancer, Neoadjuvant Chemotherapy
What this study did
NCT05125055 · Shanghai Jiao Tong University School of Medicine
2021-10-01 – 2026-12-30 · Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1, Chemotherapy
What this study did
NCT04393584 · Blokhin's Russian Cancer Research Center
2019-01-29 – 2026-01-01 · Stomach Neoplasms, Gastrointestinal Neoplasms, Docetaxel, Oxaliplatin, Fluoruracil, Irinotecan Hydrochloride
What this study did
NCT06009627 · Tianjin Medical University Cancer Institute and Hospital
2023-04-11 – 2025-09-11 · Breast Cancer
What this study did
NCT05253066 · Shengjing Hospital
2022-02-25 – 2025-01-31 · Breast Neoplasms
What this study did
NCT01404156 · Dr. Gordon Buduhan
2015-09 – 2023-08 · Esophageal Cancer, Adenocarcinoma, Esophageal, Adenocarcinoma, Gastroesophageal Junction
What this study did
NCT02766335 · SWOG Cancer Research Network
2014-07-31 – 2020-09 · Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
What this study did
NCT02777788 · Shanghai University of Traditional Chinese Medicine
2014-09 – 2019-12 · Cancer
What this study did
Phase 2 (84)
Gastric Cancer
NCT06313801 · Nizhny Novgorod Regional Clinical Oncology Center
2023-01-19 – 2027-09-01 · Gastric Cancer
What this study did
NCT05705635 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2023-01-13 – 2024-12 · Gastric Adenocarcinoma, Adenocarcinoma of Gastroesophageal Junction
What this study did
NCT01084330 · Novartis Pharmaceuticals
2010-04 – 2012-05 · Advanced Gastric Cancer, Gastro-esophageal Junction Cancer
What this study did
Head and Neck Squamous Cell Carcinoma
NCT02126969 · Susanne Arnold
2014-10 – 2021-06-15 · Head and Neck Cancer, Larynx
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07423611 · Fudan University
2026-10-01 – 2030-12-31 · Breast Cancer
What this study did
NCT07083505 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2025-08-15 – 2026-12-31 · Advanced Breast Cancer
What this study did
NCT02299999 · UNICANCER
2014-04-07 – 2025-12 · Metastatic Breast Cancer
What this study did
NCT01792050 · NewLink Genetics Corporation
2013-02 – 2017-07-07 · Metastatic Breast Cancer
What this study did
NCT00941330 · Emory University
2009-07 – 2015-05 · Breast Cancer
What this study did
NCT03887130 · Pierre Fabre Medicament
2007-03-27 – 2013-04-18 · Breast Cancer
What this study did
NCT00490646 · R-Pharm
2008-02 – 2011-11 · Metastatic Breast Cancer
What this study did
NCT00678626 · Pfizer
2009-04 – 2011-09 · Breast Cancer
What this study did
NCT00274456 · Celgene
2005-11-01 – 2011-07-01 · Metastatic Breast Cancer
What this study did
NCT00027885 · Case Comprehensive Cancer Center
2001-11 – 2010-08 · Breast Cancer
What this study did
NCT00485979 · Sanofi
2007-06 – 2010-08 · Breast Neoplasms
What this study did
NCT00546364 · R-Pharm
2008-02 – 2010-03 · Breast Neoplasms
What this study did
Metastatic Castration-Resistant Prostate Cancer
NCT07287150 · Hoffmann-La Roche
2026-03-11 – 2029-07-30 · Metastatic Castration-Resistant Prostate Cancer
What this study did
NCT03517969 · National Cancer Institute (NCI)
2019-05-29 – 2027-04-03 · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8
What this study did
NCT04028388 · Modra Pharmaceuticals
2019-07-17 – 2021-11-29 · Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
What this study did
NCT02105675 · SOTIO a.s.
2012-02 – 2017-02-20 · Prostate Cancer, Prostate Cancer Metastatic
What this study did
Non-Small Cell Lung Cancer
NCT07001618 · Gustave Roussy, Cancer Campus, Grand Paris
2025-11-17 – 2032-09 · NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT07246863 · CatalYm GmbH
2025-10-07 – 2031-10-01 · Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
What this study did
NCT07603856 · University of Chicago
2026-12-12 – 2030-06-25 · Non-Small Cell Lung Cancer, Metastatic Lung Cancer
What this study did
NCT05633667 · Gilead Sciences
2023-03-16 – 2029-09 · Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
What this study did
NCT06463665 · Genelux Corporation
2024-09-26 – 2029-07 · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
What this study did
NCT06775483 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd
2025-01-17 – 2027-11-30 · Advanced Non-small Cell Lung Cancer
What this study did
NCT04310007 · National Cancer Institute (NCI)
2020-07-13 – 2027-03-31 · Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT03833440 · Assistance Publique Hopitaux De Marseille
2019-10-08 – 2025-02 · Non-small Cell Lung Cancer
What this study did
NCT05863325 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2023-06-27 – 2024-09 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer
What this study did
NCT03739710 · GlaxoSmithKline
2019-01-24 – 2024-05-02 · Neoplasms
What this study did
NCT03971474 · SWOG Cancer Research Network
2019-05-28 – 2024-01-01 · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT04878107 · Wuhan University
2022-03-15 – 2023-10 · Non-Small Cell Lung Cancer
What this study did
NCT03647488 · Novartis Pharmaceuticals
2018-12-26 – 2020-09-07 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02450539 · Eli Lilly and Company
2015-08-06 – 2020-07-29 · Non-Small Cell Lung Cancer Stage IV
What this study did
NCT02117024 · Heat Biologics
2014-07 – 2018-04 · Non Small Cell Lung Cancer
What this study did
NCT01395758 · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
2011-07 – 2016-08 · Metastatic Non-Small Cell Lung Cancer
What this study did
NCT01646125 · Novartis Pharmaceuticals
2012-11-23 – 2015-11-04 · Advanced Non Small Cell Lung Cancer (NSCLC)
What this study did
NCT01755923 · Peking Union Medical College Hospital
2012-12 – 2014-12 · Non-small Cell Lung Cancer
What this study did
NCT01561456 · Axelar AB
2011-12 – 2013-12 · Non-small-cell Lung Cancer, Squamous Cell Carcinoma, Adenocarcinoma of the Lung
What this study did
NCT01362296 · GlaxoSmithKline
2011-09 – 2013-09 · Lung Cancer, Non-Small Cell
What this study did
NCT00308750 · Eli Lilly and Company
2006-03 – 2009-07 · Non-Small Cell Lung Cancer
What this study did
Prostate Cancer
NCT04663997 · Canadian Cancer Trials Group
2021-08-11 – 2026-12-31 · Prostate Cancer
What this study did
Phase 1/2 (16)
Metastatic Castration-Resistant Prostate Cancer
NCT07908524 · Merck Sharp & Dohme LLC
2026-12-14 – 2032-06-29 · Metastatic Castration-resistant Prostate Cancer
What this study did
Non-Small Cell Lung Cancer
NCT05904379 · Akeso
2023-07-13 – 2027-01-31 · Advanced Non-small-cell Lung Cancer
What this study did
NCT04151563 · Bristol-Myers Squibb
2021-04-15 – 2026-05-13 · Carcinoma, Non-small Cell Lung Cancer
What this study did
NCT03337698 · Hoffmann-La Roche
2017-12-27 – 2025-11-25 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT04165031 · Eli Lilly and Company
2019-11-28 – 2020-10-30 · Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Cancer
What this study did
NCT02574078 · Bristol-Myers Squibb
2015-11-23 – 2020-04-15 · Non-Small Cell Lung Cancer
What this study did
NCT02450656 · The Netherlands Cancer Institute
2015-06 – 2019-12 · Colorectal Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Carcinoma, Non-Small-Cell Lung
What this study did
Prostate Cancer
NCT06863272 · Merck Sharp & Dohme LLC
2025-07-03 – 2031-10-01 · Castration-Resistant Prostatic Cancer, Metastasis
What this study did
NCT07590934 · AstraZeneca
2026-06-03 – 2029-09-25 · Metastatic Prostate Cancer
What this study did
NCT04381832 · Arcus Biosciences, Inc.
2020-07-07 – 2024-08-30 · Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic Neoplasms, Prostatic Cancer, Castration-Resistant
What this study did
NCT00448734 · Poniard Pharmaceuticals
2006-06 – 2010-07 · Hormone Refractory Prostate Cancer
What this study did
Other / comorbidity
NCT05319873 · Jonsson Comprehensive Cancer Center
2022-04-07 – 2028-04-01 · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced HER2-Positive Breast Carcinoma, Metastatic HER2-Positive Breast Carcinoma, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT06577376 · Shanghai Runshi Pharmaceutical Technology Co., Ltd
2024-08-26 – 2027-08-26 · Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma, Expressing Human Epidermal Growth Factor Receptor-2 (HER-2), Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past
What this study did
NCT06498648 · National Cancer Institute (NCI)
2026-03-18 – 2027-01-31 · Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma, Advanced Soft Tissue Sarcoma, Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Soft Tissue Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
What this study did
NCT03693612 · GlaxoSmithKline
2018-11-26 – 2021-09-16 · Neoplasms
What this study did
NCT02401542 · Rainier Therapeutics
2015-06 – 2019-11-01 · Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases
What this study did
Phase 1 (7)
Metastatic Castration-Resistant Prostate Cancer
NCT05942001 · Jiangsu HengRui Medicine Co., Ltd.
2023-08-03 – 2026-09 · Advanced Prostate Cancer
What this study did
Non-Small Cell Lung Cancer
NCT05062980 · Genprex, Inc.
2022-03-30 – 2025-02-03 · Non Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT05251766 · Xuli Meng
2022-04-20 – 2023-06-30 · Breast Cancer, Chemotherapy Effect
What this study did
NCT01822613 · Novartis Pharmaceuticals
2013-07-26 – 2016-06-03 · Esophageal Squamous Cell Carcinoma
What this study did
NCT01611961 · Shenyang Pharmaceutical University
2012-08 – 2014-12 · Advanced Cancer
What this study did
NCT00664170 · Mast Therapeutics, Inc.
2008-04 – 2009-04 · Advanced Cancer
What this study did
NCT01268163 · Hospira, now a wholly owned subsidiary of Pfizer
2007-08 – 2008-12 · Cancer
What this study did
Phase 4 (6)
Non-Small Cell Lung Cancer
NCT00536107 · AstraZeneca
2007-10 – 2009-08 · Carcinoma, Non-Small-Cell Lung
What this study did
Other / comorbidity
NCT05420454 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2022-07-10 – 2027-12-20 · Breast Cancer
What this study did
NCT05420467 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2022-07-10 – 2027-12-20 · Breast Cancer
What this study did
NCT04136782 · Shengjing Hospital
2021-07-19 – 2026-11-30 · Breast Cancer
What this study did
NCT04182568 · Xijing Hospital
2019-08-21 – 2022-08-21 · Breast Cancer
What this study did
NCT02549677 · Ruijin Hospital
2015-10 – 2020-03 · Breast Neoplasms
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT05287308 · Chinese Academy of Medical Sciences
2022-03 – 2027-09 · Breast Cancer
What this study did
Studied as part of a combination product (3)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 3 (1)
Other / comorbidity
NCT07016737 · Ye jinjun
2024-08-01 – 2029-09-01 · Esophageal Squamous Cell Carcinoma (ESCC)
What this study did
Phase 1 (1)
Metastatic Castration-Resistant Prostate Cancer
NCT05176483 · Exelixis
2021-12-14 – 2030-06-28 · Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI)
What this study did
Early phase / not applicable (1)
Prostate Cancer
NCT07112209 · Zhujiang Hospital
2023-11-06 – 2027-11-06 · Pathological and Imaging Examinations Confirmed Metastatic Prostate Cancer
What this study did
Appears in other studies (121)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (47)
Gastric Cancer
NCT02578368 · Krankenhaus Nordwest
2016-02 – 2024-08-27 · Gastric Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT00089479 · Hoffmann-La Roche
2002-08 – 2012-05 · Breast Cancer
What this study did
NCT00917748 · Sanofi
2009-06 – 2011-03 · Prostatic Neoplasms, Breast Cancer
What this study did
NCT00091442 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2004-09 – 2008-12 · Breast Cancer
What this study did
Metastatic Castration-Resistant Prostate Cancer
NCT06439225 · Canadian Cancer Trials Group
2024-12-30 – 2030-03-31 · Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
What this study did
NCT05348577 · AstraZeneca
2022-03-25 – 2026-03-04 · Prostate Cancer
What this study did
NCT02288247 · Astellas Pharma Europe Ltd.
2014-12-01 – 2024-03-15 · Metastatic Castration Resistant Prostate Cancer
What this study did
NCT03761225 · AB Science
2014-09 – 2020-12-15 · Metastatic Castrate Resistant Prostate Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07050043 · Dr Arvindran A/L Alaga
2025-05-19 – 2030-12-31 · NSCLC (Non-small Cell Lung Carcinoma), First Line Therapy, Locally Advanced/Metastatic NSCLC
What this study did
NCT06928389 · Akeso
2025-07-08 – 2030-06 · Non-Small Cell Lung Cancer
What this study did
NCT07361484 · BeyondSpring Pharmaceuticals Inc.
2026-12-01 – 2029-12-01 · Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cance
What this study did
NCT03269162 · lihegen
2016-09-30 – 2019-09-30 · NSCLC
What this study did
NCT00805194 · Boehringer Ingelheim
2008-12-03 – 2017-11-13 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02900742 · Shanghai University of Traditional Chinese Medicine
2013-03 – 2017-06-01 · Cancer
What this study did
NCT01999673 · Peregrine Pharmaceuticals
2013-12 – 2017-03 · Non-Small-Cell Lung Cancer Stage IIIB, Non-Small-Cell Lung Cancer Stage IV, Non-Small-Cell Lung Cancer Metastatic, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, Nonsmall Cell Lung Cancer
What this study did
NCT01630733 · Achieve Life Sciences
2012-10-24 – 2016-11-17 · Non-Small Cell Lung Cancer
What this study did
NCT02766140 · Jiangsu HengRui Medicine Co., Ltd.
2016-06 – 2016-11 · Non Squamous Non Small Cell Lung
What this study did
NCT02231164 · Boehringer Ingelheim
2014-10-14 – 2015-12-24 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT01798485 · Synta Pharmaceuticals Corp.
2013-04 – 2015-12 · Non-Small-Cell Lung Adenocarcinoma, Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Metastatic
What this study did
NCT00738387 · Novartis Pharmaceuticals
2008-12 – 2010-12 · Non-Small Cell Lung Cancer
What this study did
NCT00040885 · Alliance for Clinical Trials in Oncology
2002-10 – 2008-10 · Anorexia, Cachexia, Fatigue, Lung Cancer
What this study did
Prostate Cancer
NCT01957436 · UNICANCER
2013-11-13 – 2032-12 · Metastatic Prostate Cancer
What this study did
NCT04100018 · Bristol-Myers Squibb
2020-02-06 – 2024-06-25 · Prostate Cancer
What this study did
NCT00519285 · Sanofi
2007-08 – 2012-04 · Prostatic Neoplasms, Neoplasm Metastasis
What this study did
NCT00617669 · AstraZeneca
2008-01 – 2011-07 · Prostate Cancer
What this study did
Other / comorbidity
NCT03801876 · NRG Oncology
2019-06-26 – 2036-11-07 · Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Thoracic Esophagus Squamous Cell Carcinoma
What this study did
NCT05281471 · Genelux Corporation
2022-08-31 – 2027-12 · Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
What this study did
NCT05116189 · Merck Sharp & Dohme LLC
2021-12-13 – 2027-07-16 · Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
What this study did
NCT04723875 · Huazhong University of Science and Technology
2021-01-28 – 2026-01-31 · Uterine Cervical Neoplasms, Cervical Cancer
What this study did
NCT04414566 · West China Hospital
2020-06-01 – 2025-05-30 · Nasopharyngeal Carcinoma
What this study did
NCT03199885 · National Cancer Institute (NCI)
2019-04-05 – 2025-04-04 · Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma, Recurrent Breast Adenocarcinoma, Recurrent HER2-Positive Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Unresectable Breast Carcinoma, Unresectable HER2-Positive Breast Carcinoma
What this study did
NCT03588091 · Jiangsu HengRui Medicine Co., Ltd.
2018-07-24 – 2024-01-31 · HER2-positive Breast Cancer
What this study did
NCT02426125 · Eli Lilly and Company
2015-07-13 – 2022-07-26 · Urothelial Carcinoma
What this study did
NCT03944980 · Tianjin Medical University Cancer Institute and Hospital
2019-06-01 – 2022-06-01 · IIIB/IIIC/IV Lung Cancer
What this study did
NCT00567190 · Genentech, Inc.
2008-02-12 – 2018-11-23 · Metastatic Breast Cancer
What this study did
NCT01640782 · Mario Negri Institute for Pharmacological Research
2005-02 – 2013-01 · Adenocarcinoma of the Stomach, Adenocarcinoma of the Gastroesophageal Junction
What this study did
Phase 2/3 (5)
Gastric Cancer
NCT01924819 · Australasian Gastro-Intestinal Trials Group
2009-09 – 2026-12-31 · Gastric Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT02651610 · Peregrine Pharmaceuticals
2015-12 – 2018-06 · Metastatic Breast Cancer
What this study did
Non-Small Cell Lung Cancer
Prostate Cancer
NCT05627752 · Zhongnan Hospital
2024-06-01 – 2025-12-31 · Prostate Cancer, Castrate Resistant Prostate Cancer
What this study did
Phase 2 (52)
Gastric Cancer
NCT05769725 · RenJi Hospital
2023-03-01 – 2026-03-31 · Serplulimab,Gastric Cancer, Adjuvant Therapy
What this study did
NCT05466019 · The First Hospital of Jilin University
2021-05-01 – 2024-12-01 · PD-L1 Positive Locally Advanced Patients With Resectable Gastric Cancer
What this study did
NCT02596256 · Chinese PLA General Hospital
2016-04 – 2019-02 · Gastric Cancer
What this study did
NCT00737438 · Memorial Sloan Kettering Cancer Center
2008-08 – 2015-02 · Esophageal Cancer, Gastric Cancer
What this study did
NCT00683787 · Roswell Park Cancer Institute
2008-05 – 2011-03 · Gastric Cancer
What this study did
Head and Neck Squamous Cell Carcinoma
NCT01064479 · M.D. Anderson Cancer Center
2010-02-05 – 2020-11-03 · Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous Cell Carcinoma of the Larynx, Metastatic Squamous Cell Carcinoma of the Oral Cavity, Metastatic Squamous Cell Carcinoma of the Oropharynx, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7
What this study did
NCT02353260 · Wei Guo
2014-12 – 2017-09 · Head and Neck Cancer
What this study did
NCT01285635 · University of Michigan Rogel Cancer Center
2010-06 – 2015-09 · Squamous Cell Carcinoma of the Head and Neck (SCCHN)
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT01803503 · National University Hospital, Singapore
2013-05 – 2018-04 · Solid Tumors, Breast Cancer, Non-small Cell Lung Cancer, Prostate Cancer, Gastric Cancer
What this study did
NCT02137083 · Fudan University
2014-04 – 2017-07 · Metastatic Breast Cancer
What this study did
NCT01038804 · Astellas Pharma Inc
2009-12 – 2013-06 · Breast Cancer
What this study did
NCT00217672 · Translational Oncology Research International
2005-05 – 2010-11 · Breast Cancer
What this study did
Metastatic Castration-Resistant Prostate Cancer
NCT05762536 · Erasmus Medical Center
2023-11-29 – 2028-05 · Metastatic Castration-resistant Prostate Cancer
What this study did
NCT04586543 · László Mangel
2020-05-18 – 2025-02-01 · Metastatic Castration-resistant Prostate Cancer, Adenocarcinoma of the Prostate
What this study did
Non-Small Cell Lung Cancer
NCT06141226 · Tianjin Medical University Cancer Institute and Hospital
2023-04-12 – 2028-12-30 · Non-small-cell Lung Cancer
What this study did
NCT03137771 · NRG Oncology
2017-04-07 – 2028-12 · Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
What this study did
NCT04846634 · Tianjin Medical University Cancer Institute and Hospital
2021-08 – 2028-02 · Resectable Locally Advanced Non-small Cell Lung Cancer
What this study did
NCT04396535 · Mayo Clinic
2020-10-23 – 2023-12-31 · Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT04863248 · G1 Therapeutics, Inc.
2021-04-30 – 2022-02-02 · Metastatic Non-Small Cell Lung Cancer, NSCLC, Lung Cancer
What this study did
NCT05553808 · GlaxoSmithKline
2019-01-24 – 2021-09-23 · Neoplasms
What this study did
NCT02940990 · Shanghai Chest Hospital
2016-11 – 2019-12 · NSCLC, SBRT, GM-CSF
What this study did
NCT02387216 · Elevation Oncology
2015-02-01 – 2019-01-02 · Non-Small Cell Lung Cancer, NSCLC, Adenocarcinoma, Heregulin
What this study did
NCT01703091 · Eli Lilly and Company
2012-12 – 2016-07 · Non-small Cell Lung Cancer Metastatic
What this study did
NCT01671332 · University of Wisconsin, Madison
2012-06 – 2016-06-16 · Carcinoma, Non Small Cell Lung
What this study did
NCT01784549 · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
2012-07 – 2015-12 · Non Small Cell Lung Cancer
What this study did
NCT01741155 · Spectrum Pharmaceuticals, Inc
2013-05 – 2015-07 · Non Small Cell Lung Cancer (NSCLC)
What this study did
NCT00771953 · University of Maryland, Baltimore
2008-11 – 2014-12 · Lung Cancer, Non Small Cell Lung Cancer
What this study did
NCT01107444 · Eli Lilly and Company
2010-05 – 2012-06 · Non-small Cell Lung Cancer
What this study did
NCT00862134 · Proacta, Incorporated
2009-03 – 2010-05 · Non-Small Cell Lung Cancer
What this study did
NCT00544960 · Ascenta Therapeutics
2007-09 – 2009-04 · Non-small Cell Lung Cancer
What this study did
NCT00103389 · Cellxpert Biotechnology Corp.
2004-02 – 2007-05 · Lung Cancer
What this study did
Prostate Cancer
NCT07268794 · Fudan University
2025-11-30 – 2027-12-30 · Metastatic Prostate Cancer, Prostate Cancer (Adenocarcinoma), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
What this study did
NCT01796028 · Centre Antoine Lacassagne
2013-01 – 2018-05-31 · Prostatic Neoplasms
What this study did
NCT02095717 · Centre Jean Perrin
2014-03 – 2018-04 · Prostate Cancer Metastatic Castration Resistant
What this study did
NCT01194960 · Oxford BioMedica
2010-08 – 2013-03 · Hormone Refractory Prostate Cancer
What this study did
NCT00537381 · Centocor, Inc.
2007-05 – 2009-11 · Prostatic Neoplasms
What this study did
NCT00080678 · M.D. Anderson Cancer Center
2003-05 – 2008-03 · Metastatic Cancer, Prostate Cancer
What this study did
Other / comorbidity
NCT07824869 · Shanghai Henlius Biotech
2026-10-31 – 2029-12-04 · HER2 + Breast Cancer
What this study did
NCT04872985 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2021-04-20 – 2028-12-31 · Breast Cancer, Hormone-receptor Positive Breast Cancer
What this study did
NCT07902648 · Fujian Cancer Hospital
2026-12-15 – 2028-12-31 · Gastric/Gastroesophageal Junction Adenocarcinoma, Oligometastatic Peritoneal Metastasis
What this study did
NCT06861712 · Sun Yat-sen University
2025-05-06 – 2026-12-31 · Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC), Stereotactic Body Radiation Therapy (SBRT)
What this study did
NCT05483439 · Shengjing Hospital
2021-10-20 – 2023-07-01 · Stage II-III Breast Cancer
What this study did
NCT04664972 · Henan Cancer Hospital
2018-11-23 – 2022-11-26 · Triple Negative Breast Cancer
What this study did
NCT03140553 · Guangdong Provincial People's Hospital
2016-09-01 – 2019-11-11 · HER2-Positive Breast Cancer
What this study did
NCT01780545 · Noah Hahn, M.D.
2013-04 – 2017-10 · Bladder Cancer, Urothelial Carcinoma
What this study did
NCT01660399 · Tianjin Medical University Cancer Institute and Hospital
2012-08 – 2016-12 · Squamous Cell Lung Cancer
What this study did
NCT01472029 · AIO-Studien-gGmbH
2011-12 – 2016-09-12 · Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach
What this study did
NCT01574716 · Morphotek
2012-08-07 – 2016-08-02 · Metastatic Soft Tissue Sarcoma
What this study did
NCT00880334 · Dana-Farber Cancer Institute
2006-09 – 2015-05 · Transitional Cell Carcinoma, Bladder Cancer
What this study did
Phase 1/2 (5)
Head and Neck Squamous Cell Carcinoma
NCT01204099 · Cascadian Therapeutics Inc.
2010-09 – 2014-02 · Non Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of the Head and Neck (SCCHN)
What this study did
Metastatic Castration-Resistant Prostate Cancer
NCT06615752 · Charles Drew University of Medicine and Science
2026-10 – 2029-02 · Metastatic Castration-resistant Prostate Cancer (mCRPC)
What this study did
Other / comorbidity
NCT07140393 · Jiangsu HengRui Medicine Co., Ltd.
2025-10-28 – 2028-10 · Solid Tumor
What this study did
NCT02659020 · Eli Lilly and Company
2016-03-01 – 2021-04-27 · Soft Tissue Sarcoma
What this study did
NCT02048540 · Chinese PLA General Hospital
2009-02 – 2013-12 · Locally Advanced Gastric Carcinoma
What this study did
Phase 1 (5)
Prostate Cancer
NCT06769425 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2025-05-07 – 2026-08-31 · Recurrent Ovarian Cancer, HER2-negative, Advanced Breast Cancer, TNBC, Advanced Prostate Cancer, Advanced Gastric Cancer
What this study did
Other / comorbidity
NCT05013268 · Ruijin Hospital
2021-09 – 2022-12 · Cervical Squamous Cell Carcinoma
What this study did
NCT05084456 · Modra Pharmaceuticals
2017-07 – 2020-04 · Solid Tumor, Adult, Impaired Liver Function
What this study did
NCT05242926 · Modra Pharmaceuticals
2017-10 – 2018-06 · Solid Tumor, Adult
What this study did
Phase 4 (1)
Non-Small Cell Lung Cancer
NCT00813332 · Simcere Pharmaceutical Co., Ltd
2008-10 – 2010-10 · Advanced NSCLC, Recurrent NSCLC
What this study did
Early phase / not applicable (6)
Gastric Cancer
NCT04595929 · St. Petersburg State Pavlov Medical University
2020-02-10 – 2029-01-10 · Peritoneal Carcinomatosis, Gastric Cancer
What this study did
NCT04886193 · Guangdong Provincial Hospital of Traditional Chinese Medicine
2021-04-16 – 2023-05 · Chemotherapy, Gastric Cancer
What this study did
Non-Small Cell Lung Cancer
NCT06484491 · University Medical Center Groningen
2025-09-01 – 2028-10-01 · Carcinoma, Non-Small-Cell Lung
What this study did
Other / comorbidity
NCT02627807 · Sun Yat-sen University
2015-12 – 2022-12 · Nasopharyngeal Neoplasms
What this study did
NCT03756064 · Zhejiang Cancer Hospital
2019-08-01 – 2021-07-31 · Breast Cancer, Neoplasm, Breast, Breast Diseases
What this study did
NCT01551589 · Chengya Chou
2012-03 – 2017-07 · Esophageal Squamous Cell Carcinoma
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for HR+/HER2- Metastatic Breast Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Docetaxel (Taxotere): this drugApprovedSmall moleculeMicrotubules (tubulin)Partial signal
NCT00002662: ORR (the registered first objective) 32% vs 25% (P=.10); OS 15.4 vs 12.7 months (P=.03) and TTP 5.7 vs 3.6 months (P<.0001) favored docetaxel. missed
Abemaciclib (Verzenio)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4)
NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5)
Alpelisib (BYL719)ApprovedSmall moleculePI3K-alphaReliable signal
NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36)
AnastrozoleApprovedSmall moleculeAromatasenot yet graded
NCT00291759: Recurrence-free survival, 2yr tamoxifen then 3yr anastrozole vs 5yr tamoxifen: HR 0.80 (95% CI 0.63-1.01), P=.06 (not statistically significant) missed phase 3 result · pivotal pending
NCT00300508: At a median follow-up of 62.3 months, women who received anastrozole (n=387) had a statistically significantly reduced risk of recurrence (locoregional recurrence, contralateral breast cancer or distant metastasis) versus women who received no further treatment (n=469): hazard ratio 0.62 (95% CI 0.40-0.96), P=.031. phase 3 result · pivotal pending
Camizestrant (Etcamah)ApprovedSmall moleculeEstrogen receptorReliable signal
NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001
NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81)
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
CapivasertibApprovedSmall moleculeAKT (inhibitor)Reliable signal
NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7)
NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5)
ElacestrantApprovedSmall moleculeEstrogen receptorPartial signal
NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14)
Eribulin MesylateApprovedSmall moleculeTubulin / microtubulesPartial signal
NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms
NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Weak signal
NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164)
NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14)
ExemestaneApprovedSmall moleculeAromatasePartial signal
NCT00002777: Objective response rate: 46% exemestane vs 31% tamoxifen (odds ratio 1.85, 95% CI 1.21-2.82, P=.005). Median progression-free survival (the trial's primary endpoint): 9.9 months exemestane vs 5.8 months tamoxifen; long-term log-rank P=.121 (not statistically significant). missed
Fulvestrant (Faslodex)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59)
NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010).
Gedatolisib (Revtorpyk)ApprovedSmall moleculePI3K (class I isoforms) and mTORC1/mTORC2Partial signal
NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001.
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Weak signal
NCT00128310: Median progression-free survival: 6.0 months (gemcitabine + vinorelbine) vs 4.0 months (vinorelbine alone); hazard ratio 0.66 (p=0.0028). Overall survival not significantly different (15.9 vs 16.4 months, p=0.8046)
NCT00006459: Eli Lilly's pivotal phase III global registration trial of gemcitabine + paclitaxel vs paclitaxel alone in anthracycline-pretreated advanced breast cancer, matching this listing's title/sponsor. Primary endpoint (overall survival): 18.6 vs 15.8 months, HR 0.78 (95% CI 0.64-0.96), p=0.0187, favoring the gemcitabine combination.
GoserelinApprovedPeptideGnRH receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
Imlunestrant (Inluriyo)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001
Inavolisib (Itovebi)ApprovedSmall moleculePI3K-alphaReliable signal
NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3)
IxabepiloneApprovedSmall moleculeMicrotubules (tubulin)Partial signalFeatured results are non-efficacy only in this race
LetrozoleApprovedSmall moleculeAromatasenot yet graded
NCT00003140: Estimated 4-year disease-free survival: letrozole 93% vs placebo 87% (75 vs 132 recurrences/new cancers out of 5187 enrolled); P<=0.001 phase 3 result · pivotal pending
NCT00004205: Disease-free survival (primary endpoint), letrozole vs tamoxifen: 5-year DFS 84.0% vs 81.4%; HR 0.81 (95% CI 0.70-0.93), P=0.003, at median follow-up 25.8 months (351 vs 428 events; N=8010). phase 3 result · pivotal pending
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed
OlaparibApprovedSmall moleculePARPPartial signal
NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3)
NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17)
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6)
NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1)
RibociclibApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3)
NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4)
Sacituzumab GovitecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4)
TalazoparibApprovedSmall moleculePARPPartial signal
NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7)
Tamoxifen (Soltamox)ApprovedSmall moleculeEstrogen receptornot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1)
Vepdegestrant (Veppanu)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025).
NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41)
AfuresertibPhase 3Small moleculeAKT (inhibitor)Partial signal
NCT04851613: Primary endpoint, progression-free survival: median 7.6 months with afuresertib plus fulvestrant vs 2.0 months with placebo plus fulvestrant (sponsor topline, 2026-04-15).
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
AtirmociclibPhase 3Small moleculeCDK4Partial signal
NCT06465368: Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14 (Day 14): PF-07220060 + Letrozole 88.2% (95% CI 76.6-94.5) vs Letrozole Alone 17.9% (95% CI 10.0-29.8)
BEBT-209Phase 3Small moleculeCDK4 (selective)not yet gradedNo reviewed efficacy summary in this indication
Beruzatatug PelitecanPhase 3Antibody–drug conjugateHER3not yet gradedNo reviewed efficacy summary in this indication
BGB-43395Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
BireociclibPhase 3Small moleculeCDK2/4/6Reliable signal
NCT05077449: BRIGHT-2 (NCT05077449), primary endpoint median PFS: bireociclib (XZP-3287) + fulvestrant 14.7 months vs placebo + fulvestrant 7.3 months; HR 0.54 (95% CI 0.40-0.74); p<0.001
ChidamidePhase 3Small moleculeHDACReliable signal
NCT02482753: Investigator-assessed median PFS: 7.4 months (95% CI 5.5-9.2) chidamide+exemestane vs 3.8 months (95% CI 3.7-5.5) placebo+exemestane; hazard ratio 0.755, p=0.0336
CulmerciclibPhase 3Small moleculeCDK2/CDK4/CDK6, CDK2/4/6/CDK4Partial signal
NCT05375461: Median investigator-assessed PFS: 16.6 months (culmerciclib + fulvestrant) vs 7.5 months (placebo + fulvestrant); HR 0.36 (95% CI 0.26-0.51), P<0.001, meeting the primary endpoint.
DalpiciclibPhase 3Small moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
Denosumab (Xgeva)Phase 3Monoclonal antibodyRANKLnot yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 3Antibody–drug conjugateHER2Partial signal
NCT03052634: Confirmed ORR at 2.0 mg/kg Q2W: 42.9% (9/21) in HER2-overexpression and 33.3% (22/66) in HER2-low advanced breast cancer; median PFS 5.7 and 5.1 months
GiredestrantPhase 3Small moleculeEstrogen receptorPartial signal
NCT04546009: persevERA (NCT04546009), primary endpoint investigator-assessed PFS: giredestrant plus palbociclib median PFS 33.1 months vs letrozole plus palbociclib 28.2 months; HR 0.89 (95% CI 0.76-1.05); p=.1553. missed
HRS-6209Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
HRS-8080Phase 3Small moleculeEstrogen receptor (degrader)not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
JS105Phase 3Small moleculePI3K-alpha (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication
NTQ1062Phase 3Small moleculeAKT (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
PalazestrantPhase 3Small moleculeEstrogen receptorWeak signalNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signalNo reviewed efficacy summary in this indication
PembrolizumabPhase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
PrifetrastatPhase 3Small moleculeKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
SaruparibPhase 3Small moleculePARP1 inhibitor (next-gen)not yet gradedNo reviewed efficacy summary in this indication
SHR-6209Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
Sirolimus For Injection (Albumin-Bound)Phase 3Small moleculemTOR (mechanistic target of rapamycin complex 1), via FKBP-12not yet gradedNo reviewed efficacy summary in this indication
TaragarestrantPhase 3Small moleculeEstrogen receptornot yet gradedNo reviewed efficacy summary in this indication
TersolisibPhase 3Small moleculePI3K-alpha (mutant-selective, allosteric)not yet gradedNo reviewed efficacy summary in this indication
Tibremciclib (Kangmeina)Phase 3Small moleculeCDK4 and CDK6Partial signal
NCT05433480: Investigator-assessed PFS: tibremciclib plus fulvestrant median 16.5 months (95% CI 12.8 to 16.6) vs placebo plus fulvestrant 5.6 months (95% CI 4.5 to 9.2); HR 0.37 (95% CI 0.27 to 0.52), P<.001
Trastuzumab PamirtecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
UtidelonePhase 3Small moleculeTubulin / microtubulesnot yet gradedNo reviewed efficacy summary in this indication
Zoledronic AcidPhase 3Small moleculeFarnesyl pyrophosphate synthase (FPPS)not yet gradedNo reviewed efficacy summary in this indication
MRT-2359Phase 1/2Small moleculeGSPT1not yet gradedNo reviewed efficacy summary in this indication
BuparlisibDiscontinuedSmall moleculePI3K inhibitor (pan-class I)Reliable signal
NCT01610284: Progression Free Survival (PFS) Based on Local Investigator Assessment - Full Analysis Set (FAS) in Full Population, Main Study Cohort and PI3K Unknown Cohort (Date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to approximately 4 years): BKM120 100mg + Fulvestrant — FAS-Full population: 6.9 Months (95% CI 6.8 to 7.8); FAS-Main cohort: 6.8 Months (95% CI 5 to 7); FAS-PI3K pathway activated: 6.8 Months (95% CI 4.9 to 7.1); FAS-PI3K pathway non-activated: 6.9 Months (95% CI 4.6 to 7.2); FAS-PI3K pathway unknown: 8.7 Months (95% CI 7 to 12.4) vs Placebo + Fulvestrant — FAS-Full population: 5 Months (95% CI 4 to 5.2); FAS-Main cohort: 4.5 Months (95% CI 3.3 to 5); FAS-PI3K pathway activated: 4 Months (95% CI 3.1 to 5.2); FAS-PI3K pathway non-activated: 4.6 Months (95% CI 3.3 to 5.1); FAS-PI3K pathway unknown: 6.8 Months (95% CI 5 to 8.4)
Sabizabulin
Discontinued
Small moleculeMicrotubules (tubulin)
not yet graded(overall)
No reviewed efficacy summary in this indication

Large race: only the 64 furthest-along competitors are listed; 42 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(182 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Taxotere (Docetaxel) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (27)
November 2026 (4)
Phase 2Prostate CancerActive not recruiting
Est. primary completion 2026-11 · NCT03951831 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal CarcinomaActive not recruiting
Est. primary completion 2026-11 · NCT06118333 · CT.gov ↗
What to watch
Phase 1/2Advanced MTAP-null Solid TumorsActive not recruiting
Est. primary completion 2026-11-30 · NCT05094336 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-11-30 · NCT06749886 · CT.gov ↗
What to watch
December 2026 (23)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT02889666 · CT.gov ↗
What to watch
Phase 2/3Prostate CancerRecruiting
Est. primary completion 2026-12 · NCT03258320 · CT.gov ↗
What to watch
Phase 3Metastatic Castration-Resistant Prostate CancerRecruiting
Est. primary completion 2026-12 · NCT03903835 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2026-12 · NCT05054439 · CT.gov ↗
What to watch
Phase 2Triple Negative Breast Cancer, Breast CancerActive not recruiting
Est. primary completion 2026-12 · NCT05645380 · CT.gov ↗
What to watch
Phase 2Sinonasal Undifferentiated CarcinomaRecruiting
Est. primary completion 2026-12 · NCT05925491 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT06382129 · CT.gov ↗
What to watch
Phase 1/2Prostate CancerRecruiting
Est. primary completion 2026-12 · NCT06568094 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT06943820 · CT.gov ↗
What to watch
Phase 1/2Pediatric Sarcoma, Refractory, Pediatric Sarcoma, RelapsedRecruiting
Est. primary completion 2026-12-01 · NCT05634369 · CT.gov ↗
What to watch
Phase 1/2Metastatic Castration-Resistant Prostate CancerRecruiting
Est. primary completion 2026-12-01 · NCT06480110 · CT.gov ↗
What to watch
Phase 1Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C MutationActive not recruiting
Est. primary completion 2026-12-17 · NCT04185883 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-24 · NCT06783647 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12-25 · NCT06525350 · CT.gov ↗
What to watch
Phase 1Advanced Solid Tumor CancerRecruiting
Est. primary completion 2026-12-30 · NCT07381829 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT04140526 · CT.gov ↗
What to watch
Phase 2Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8Recruiting
Est. primary completion 2026-12-31 · NCT04329065 · CT.gov ↗
What to watch
Phase 1/2Prostate CancerRecruiting
Est. primary completion 2026-12-31 · NCT04633252 · CT.gov ↗
What to watch
Phase 2Bladder Cancer, Non-muscle InvasiveActive not recruiting
Est. primary completion 2026-12-31 · NCT05024734 · CT.gov ↗
What to watch
Phase 3Locally Advanced Gastric Adenocarcinoma, Chemotherapy EffectRecruiting
Est. primary completion 2026-12-31 · NCT05813015 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2026-12-31 · NCT05867420 · CT.gov ↗
What to watch
Phase 2Breast NeoplasmsRecruiting
Est. primary completion 2026-12-31 · NCT05978648 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT07330050 · CT.gov ↗
What to watch
2027 (74)
January 2027 (4)
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2027-01 · NCT06741644 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-01 · NCT06879717 · CT.gov ↗
What to watch
Phase 2Metastatic Castration-Resistant Prostate CancerActive not recruiting
Est. primary completion 2027-01-31 · NCT04015622 · CT.gov ↗
What to watch
Phase 2Gastric CancerActive not recruiting
Est. primary completion 2027-01-31 · NCT07257575 · CT.gov ↗
What to watch
February 2027 (2)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-02 · NCT05076760 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-02 · NCT06228326 · CT.gov ↗
What to watch
March 2027 (4)
Phase 2Prostate CancerActive not recruiting
Est. primary completion 2027-03 · NCT03456843 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-03 · NCT06632951 · CT.gov ↗
What to watch
Phase 1NeoplasmsActive not recruiting
Est. primary completion 2027-03-01 · NCT02817633 · CT.gov ↗
What to watch
Phase 2GC/GEJCNot yet recruiting
Est. primary completion 2027-03-01 · NCT06684158 · CT.gov ↗
What to watch
April 2027 (7)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-04 · NCT04540692 · CT.gov ↗
What to watch
Phase 1/2Locally Advanced Unresectable Esophageal Squamous CarcinomaNot yet recruiting
Est. primary completion 2027-04 · NCT06136988 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04 · NCT06409390 · CT.gov ↗
What to watch
Phase 3Prostate CancerActive not recruiting
Est. primary completion 2027-04-01 · NCT03574571 · CT.gov ↗
What to watch
Phase 2/3Gastric CancerRecruiting
Est. primary completion 2027-04-25 · NCT06028737 · CT.gov ↗
What to watch
Phase 3Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-04-30 · NCT06102395 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-04-30 · NCT06947291 · CT.gov ↗
What to watch
May 2027 (4)
Phase 2Neoplasms, Child, AdolescentRecruiting
Est. primary completion 2027-05 · NCT05999994 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05-30 · NCT06421298 · CT.gov ↗
What to watch
Phase 2Gastric CancerActive not recruiting
Est. primary completion 2027-05-31 · NCT03421288 · CT.gov ↗
What to watch
Phase 1/2Recurrent Osteosarcoma, Refractory OsteosarcomaActive not recruiting
Est. primary completion 2027-05-31 · NCT03598595 · CT.gov ↗
What to watch
June 2027 (8)
Phase 1Gastroesophageal AdenocarcinomaRecruiting
Est. primary completion 2027-06 · NCT05733689 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06 · NCT07070440 · CT.gov ↗
What to watch
Phase 2Prostate CancerRecruiting
Est. primary completion 2027-06-01 · NCT04812366 · CT.gov ↗
What to watch
Phase 1Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-06-20 · NCT04722523 · CT.gov ↗
What to watch
Phase 2Neoplasm MetastasisActive not recruiting
Est. primary completion 2027-06-30 · NCT00781612 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT03178552 · CT.gov ↗
What to watch
Phase 2Gastric CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT03505320 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-06-30 · NCT05184803 · CT.gov ↗
What to watch
July 2027 (2)
Phase 1/2Triple Negative Breast CancerRecruiting
Est. primary completion 2027-07-01 · NCT04947189 · CT.gov ↗
What to watch
Phase 2Prostate CancerActive not recruiting
Est. primary completion 2027-07-15 · NCT05189457 · CT.gov ↗
What to watch
August 2027 (6)
Phase 2Bladder CancerRecruiting
Est. primary completion 2027-08 · NCT06488222 · CT.gov ↗
What to watch
Phase 4Breast CancerNot yet recruiting
Est. primary completion 2027-08-01 · NCT07093931 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08-30 · NCT07925866 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08-31 · NCT05777278 · CT.gov ↗
What to watch
Phase 1Prostate CancerRecruiting
Est. primary completion 2027-08-31 · NCT05818683 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08-31 · NCT07306624 · CT.gov ↗
What to watch
September 2027 (5)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-09 · NCT05592626 · CT.gov ↗
What to watch
Phase 2Gastroesophageal Junction Adenocarcinoma, Gastric AdenocarcinomaActive not recruiting
Est. primary completion 2027-09 · NCT07776639 · CT.gov ↗
What to watch
Phase 1/2Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Soft Tissue Sarcoma AdultRecruiting
Est. primary completion 2027-09-29 · NCT04577014 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-09-30 · NCT04884282 · CT.gov ↗
What to watch
Phase 1Prostate CancerRecruiting
Est. primary completion 2027-09-30 · NCT05997615 · CT.gov ↗
What to watch
October 2027 (4)
Phase 1Gastro-esophageal Junction (GEJ) Cancer, Esophagus CancerRecruiting
Est. primary completion 2027-10-01 · NCT07700420 · CT.gov ↗
What to watch
Phase 1/2Metastatic Castration-Resistant Prostate CancerActive not recruiting
Est. primary completion 2027-10-22 · NCT02861573 · CT.gov ↗
What to watch
Phase 2Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8 …Active not recruiting
Est. primary completion 2027-10-31 · NCT04266249 · CT.gov ↗
What to watch
Phase 1Cervical Esophagus Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8 …Recruiting
Est. primary completion 2027-10-31 · NCT04615013 · CT.gov ↗
What to watch
November 2027 (6)
Early phase / not applicableHypopharyngeal CarcinomaRecruiting
Est. primary completion 2027-11 · NCT05494190 · CT.gov ↗
What to watch
Phase 2Non Muscle Invasive Bladder CancerRecruiting
Est. primary completion 2027-11 · NCT06663137 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-11-01 · NCT07059611 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-11-14 · NCT07220135 · CT.gov ↗
What to watch
Phase 3Metastatic Castration-Resistant Prostate CancerRecruiting
Est. primary completion 2027-11-19 · NCT07225946 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-11-30 · NCT06123338 · CT.gov ↗
What to watch
December 2027 (22)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT05431270 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12 · NCT05676931 · CT.gov ↗
What to watch
Phase 3Metastatic Castration-Resistant Prostate CancerRecruiting
Est. primary completion 2027-12 · NCT06520345 · CT.gov ↗
What to watch
Phase 2TNBC, TNBC - Triple-Negative Breast Cancer, Early Stage Triple-Negative Breast CarcinomaRecruiting
Est. primary completion 2027-12 · NCT07017673 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT07358806 · CT.gov ↗
What to watch
Phase 2mHSPCRecruiting
Est. primary completion 2027-12 · NCT07503379 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-01 · NCT05910827 · CT.gov ↗
What to watch
Phase 1Prostate CancerNot yet recruiting
Est. primary completion 2027-12-01 · NCT07516704 · CT.gov ↗
What to watch
Phase 2/3Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-12-15 · NCT05063552 · CT.gov ↗
What to watch
Phase 2Advanced Solid TumorRecruiting
Est. primary completion 2027-12-15 · NCT07669415 · CT.gov ↗
What to watch
Phase 2HER2-positive Breast Cancer, Breast CancerRecruiting
Est. primary completion 2027-12-29 · NCT07102381 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-12-31 · NCT01154920 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-12-31 · NCT04840264 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT05726370 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-31 · NCT06616584 · CT.gov ↗
What to watch
Phase 1/2Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8Recruiting
Est. primary completion 2027-12-31 · NCT06704191 · CT.gov ↗
What to watch
Phase 1/2Gastric CancerRecruiting
Est. primary completion 2027-12-31 · NCT06732856 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT07214987 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07246317 · CT.gov ↗
What to watch
Phase 2HER2-positive Early-stage Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT07402473 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-31 · NCT07528274 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaEnrolling by invitation
Est. primary completion 2027-12-31 · NCT07618624 · CT.gov ↗
What to watch
2028 (29)
January 2028 (2)
Phase 2/3NPC, HNSCC, Recurrence, MetastasisNot yet recruiting
Est. primary completion 2028-01-01 · NCT06719479 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-01-10 · NCT06223568 · CT.gov ↗
What to watch
February 2028 (2)
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-02-01 · NCT06940180 · CT.gov ↗
What to watch
Phase 2Solid TumorsRecruiting
Est. primary completion 2028-02-16 · NCT07415031 · CT.gov ↗
What to watch
March 2028 (1)
Phase 2Squamous Cell Carcinoma, the Nasal Cavity, Paranasal SinusesRecruiting
Est. primary completion 2028-03-30 · NCT05027633 · CT.gov ↗
What to watch
June 2028 (8)
Phase 2Breast Cancer, HER2-positive Breast CancerRecruiting
Est. primary completion 2028-06 · NCT06441890 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-06-01 · NCT07805135 · CT.gov ↗
What to watch
Phase 3Locally Advanced or Metastatic Breast CancerActive not recruiting
Est. primary completion 2028-06-15 · NCT05296798 · CT.gov ↗
What to watch
Phase 3Gastric CancerRecruiting
Est. primary completion 2028-06-30 · NCT01935778 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2028-06-30 · NCT04437329 · CT.gov ↗
What to watch
Phase 3Non-muscle Invasive Bladder Cancer With Carcinoma in SituRecruiting
Est. primary completion 2028-06-30 · NCT06545955 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-30 · NCT06868732 · CT.gov ↗
What to watch
Phase 3Breast Cancer Early Stage Breast Cancer (Stage 1-3)Recruiting
Est. primary completion 2028-06-30 · NCT07797218 · CT.gov ↗
What to watch
July 2028 (3)
Phase 1Muscle Invasive Bladder Urothelial CarcinomaEnrolling by invitation
Est. primary completion 2028-07-01 · NCT06204614 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-07-01 · NCT06951646 · CT.gov ↗
What to watch
Phase 2Salivary Gland Carcinoma, Precision TherapyRecruiting
Est. primary completion 2028-07-10 · NCT06145308 · CT.gov ↗
What to watch
August 2028 (5)
Phase 3Triple-negative Breast CancerNot yet recruiting
Est. primary completion 2028-08 · NCT06795503 · CT.gov ↗
What to watch
Phase 2Breast Cancer, HER 2 Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, Stage 1-3Not yet recruiting
Est. primary completion 2028-08 · NCT07102940 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-08-01 · NCT05800587 · CT.gov ↗
What to watch
Phase 2Locally Advanced Sinonasal CarcinomaNot yet recruiting
Est. primary completion 2028-08-01 · NCT07645846 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2028-08-01 · NCT07900516 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, High-risk Breast Cancer, Early-Stage Breast CancerNot yet recruiting
Est. primary completion 2028-09-01 · NCT07947823 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-10 · NCT06841055 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-10 · NCT07609251 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Neoplasms of Connective and Soft Tissue With an Unspecified Anatomical SiteNot yet recruiting
Est. primary completion 2028-11-30 · NCT07547592 · CT.gov ↗
What to watch
December 2028 (4)
Phase 1/2Advanced Solid TumorRecruiting
Est. primary completion 2028-12-25 · NCT06682780 · CT.gov ↗
What to watch
Phase 1/2Urothelial Carcinoma, Bladder CancerActive not recruiting
Est. primary completion 2028-12-31 · NCT03317158 · CT.gov ↗
What to watch
Phase 1Solid TumorRecruiting
Est. primary completion 2028-12-31 · NCT05382559 · CT.gov ↗
What to watch
Phase 2Prostate CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07730580 · CT.gov ↗
What to watch
2029 (27)
January 2029 (4)
Phase 2Prostate CancerActive not recruiting
Est. primary completion 2029-01 · NCT06734130 · CT.gov ↗
What to watch
Phase 1/2Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma …Recruiting
Est. primary completion 2029-01-08 · NCT06324357 · CT.gov ↗
What to watch
Phase 1/2Metastatic Castration-Resistant Prostate CancerActive not recruiting
Est. primary completion 2029-01-15 · NCT06353386 · CT.gov ↗
What to watch
Phase 2/3Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid TumorsRecruiting
Est. primary completion 2029-01-29 · NCT06279130 · CT.gov ↗
What to watch
February 2029 (1)
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-02-28 · NCT07472647 · CT.gov ↗
What to watch
March 2029 (2)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-03 · NCT06266299 · CT.gov ↗
What to watch
Phase 2Stage III Sinonasal Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7Active not recruiting
Est. primary completion 2029-03-31 · NCT03493425 · CT.gov ↗
What to watch
April 2029 (3)
Phase 2Gastroesophageal AdenocarcinomaNot yet recruiting
Est. primary completion 2029-04 · NCT07625930 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-04 · NCT07699757 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-04-30 · NCT06632327 · CT.gov ↗
What to watch
May 2029 (3)
Phase 1Advanced Solid TumorRecruiting
Est. primary completion 2029-05-01 · NCT06241456 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2029-05-01 · NCT07527806 · CT.gov ↗
What to watch
Phase 2Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8 …Recruiting
Est. primary completion 2029-05-25 · NCT06078709 · CT.gov ↗
What to watch
June 2029 (2)
Phase 3Hormone Receptor Positive HER-2 Negative Breast CancerRecruiting
Est. primary completion 2029-06 · NCT05901428 · CT.gov ↗
What to watch
Phase 2Triple Negative Breast CancerRecruiting
Est. primary completion 2029-06 · NCT06291064 · CT.gov ↗
What to watch
July 2029 (2)
Phase 2Prostate CancerNot yet recruiting
Est. primary completion 2029-07 · NCT07907653 · CT.gov ↗
What to watch
Phase 2Metastatic Castration-Resistant Prostate CancerRecruiting
Est. primary completion 2029-07-05 · NCT07698535 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-08-31 · NCT03228667 · CT.gov ↗
What to watch
September 2029 (2)
Phase 2Locally Advanced Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2029-09 · NCT07828873 · CT.gov ↗
What to watch
Phase 2Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 …Recruiting
Est. primary completion 2029-09-06 · NCT05541016 · CT.gov ↗
What to watch
November 2029 (1)
Phase 3Non-muscle-invasive Bladder CancerActive not recruiting
Est. primary completion 2029-11-01 · NCT05538663 · CT.gov ↗
What to watch
December 2029 (6)
Phase 3Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) …Not yet recruiting
Est. primary completion 2029-12 · NCT07464145 · CT.gov ↗
What to watch
Phase 1Advanced Solid Tumor, Metastatic Solid Tumor, Advanced and/or Metastatic Solid TumorsNot yet recruiting
Est. primary completion 2029-12-30 · NCT06724042 · CT.gov ↗
What to watch
Phase 2Non-Muscle-Invasive Bladder Cancer, BCG-Unresponsive Bladder CancerRecruiting
Est. primary completion 2029-12-30 · NCT07747740 · CT.gov ↗
What to watch
Phase 2Non Muscle Invasive Bladder CancerRecruiting
Est. primary completion 2029-12-31 · NCT06972615 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2029-12-31 · NCT07354984 · CT.gov ↗
What to watch
Phase 1/2Germ Cell CancerNot yet recruiting
Est. primary completion 2029-12-31 · NCT07850973 · CT.gov ↗
What to watch
2030 (9)
February 2030 (1)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-02 · NCT05142189 · CT.gov ↗
What to watch
March 2030 (3)
Phase 2Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer …Recruiting
Est. primary completion 2030-03-30 · NCT06439693 · CT.gov ↗
What to watch
Phase 3Prostate CancerRecruiting
Est. primary completion 2030-03-31 · NCT07333066 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2030-03-31 · NCT07872722 · CT.gov ↗
What to watch
April 2030 (1)
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2030-04-30 · NCT05719558 · CT.gov ↗
What to watch
June 2030 (1)
Phase 2Gastroesophageal Junction (GEJ) AdenocarcinomaRecruiting
Est. primary completion 2030-06 · NCT07018570 · CT.gov ↗
What to watch
July 2030 (1)
Phase 2/3Prostate CancerRecruiting
Est. primary completion 2030-07-31 · NCT06282588 · CT.gov ↗
What to watch
August 2030 (1)
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2030-08-31 · NCT05954312 · CT.gov ↗
What to watch
November 2030 (1)
Phase 2Bladder Cancer, Non-muscle Invasive Bladder Cancer, Low GradeNot yet recruiting
Est. primary completion 2030-11-30 · NCT06227065 · CT.gov ↗
What to watch
2031 (9)
March 2031 (2)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2031-03-01 · NCT05919537 · CT.gov ↗
What to watch
Phase 3Prostate CancerRecruiting
Est. primary completion 2031-03-14 · NCT06592924 · CT.gov ↗
What to watch
April 2031 (1)
Phase 3Prostate CancerRecruiting
Est. primary completion 2031-04 · NCT06320067 · CT.gov ↗
What to watch
July 2031 (1)
Phase 3HER2 Positive Early Breast CancerRecruiting
Est. primary completion 2031-07-01 · NCT05883852 · CT.gov ↗
What to watch
August 2031 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2031-08-31 · NCT04895709 · CT.gov ↗
What to watch
September 2031 (1)
Phase 2Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 …Recruiting
Est. primary completion 2031-09-20 · NCT06042569 · CT.gov ↗
What to watch
November 2031 (1)
Phase 3Prostate CancerRecruiting
Est. primary completion 2031-11-11 · NCT06931340 · CT.gov ↗
What to watch
December 2031 (2)
Phase 2Squamous Cell CarcinomaRecruiting
Est. primary completion 2031-12-16 · NCT02128906 · CT.gov ↗
What to watch
Phase 2Prostate CancerNot yet recruiting
Est. primary completion 2031-12-31 · NCT07730151 · CT.gov ↗
What to watch
2032 (3)
May 2032 (1)
Phase 3Endometrial CancerRecruiting
Est. primary completion 2032-05-24 · NCT06952504 · CT.gov ↗
What to watch
August 2032 (1)
Phase 2Prostate CancerNot yet recruiting
Est. primary completion 2032-08 · NCT07645326 · CT.gov ↗
What to watch
December 2032 (1)
Phase 2Breast Cancer, Triple Negative Breast CancerNot yet recruiting
Est. primary completion 2032-12 · NCT07743632 · CT.gov ↗
What to watch
2033 (2)
January 2033 (1)
Phase 2Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma, Carcinoma in Situ (CIS) …Recruiting
Est. primary completion 2033-01-01 · NCT07322263 · CT.gov ↗
What to watch
March 2033 (1)
Phase 3Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 …Recruiting
Est. primary completion 2033-03-31 · NCT05929768 · CT.gov ↗
What to watch
2034 (1)
July 2034 (1)
Phase 2Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast CancerRecruiting
Est. primary completion 2034-07-01 · NCT06348134 · CT.gov ↗
What to watch
2036 (1)
October 2036 (1)
Phase 1/2Metastatic Castration-Resistant Prostate CancerRecruiting
Est. primary completion 2036-10-01 · NCT07667400 · CT.gov ↗
What to watch

See the full readout calendar ↗